Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Daniel Von Hoff

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Activities & Behaviors

Drug Evaluation

Procedures

Anatomy

Concepts & Ideas

Living Beings

Mice

Physiology

Cell Division

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Drygin Denis; Siddiqui-Jain Adam; O'Brien Sean; Schwaebe Michael; Lin Amy; Bliesath Josh; Ho Caroline B; Proffitt Chris; Trent Katy; Whitten Jeffrey P; Lim John K C; Von Hoff Daniel; Anderes Kenna; Rice William G
Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.
Boone Susan L; Jameson Gayle; Von Hoff Daniel; Lacouture Mario E
Blackberry-induced hand-foot skin reaction to sunitinib.
Von Hoff Daniel D; Korn Ron; Mousses Spyro
Pancreatic cancer--could it be that simple? A different context of vulnerability.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Daniel Von Hoff (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Drygin Denis; Siddiqui-Jain Adam; O'Brien Sean; Schwaebe Michael; Lin Amy; Bliesath Josh; Ho Caroline B; Proffitt Chris; Trent Katy; Whitten Jeffrey P; Lim John K C; Von Hoff Daniel; Anderes Kenna; Rice William G
Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.
Cancer research 2009;69(19):7653-61.
2009: Boone Susan L; Jameson Gayle; Von Hoff Daniel; Lacouture Mario E
Blackberry-induced hand-foot skin reaction to sunitinib.
Investigational new drugs 2009;27(4):389-90.
2009: Von Hoff Daniel D; Korn Ron; Mousses Spyro
Pancreatic cancer--could it be that simple? A different context of vulnerability.
Cancer cell 2009;16(1):7-8.
2009: Wang Hong; Stephens Bret; Von Hoff Daniel D; Han Haiyong
Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells.
Pancreas 2009;38(5):551-7.
2009: Sonpavde Guru; Galsky Matthew D; Hutson Thomas E; Von Hoff Daniel D
Patient selection for phase II trials.
American journal of clinical oncology 2009;32(2):216-9.
2009: Colvin Joshua; Monine Michael I; Faeder James R; Hlavacek William S; Von Hoff Daniel D; Posner Richard G
Simulation of large-scale rule-based models.
Bioinformatics (Oxford, England) 2009;25(7):910-7.
2009: Borad Mitesh J; Saadati Hamid; Lakshmipathy Arun; Campbell Elizabeth; Hopper Patricia; Jameson Gayle; Von Hoff Daniel D; Saif M Wasif
Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature.
The Yale journal of biology and medicine 2009;82(1):1-6.
2009: DiMaio Michael A; Mikhailov Alexei; Rieder Conly L; Von Hoff Daniel D; Palazzo Robert E
The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation.
Molecular cancer therapeutics 2009;8(3):592-601.
2009: Riley Christopher J; Engelhardt Kevin P; Saldanha Jose W; Qi Wenqing; Cooke Laurence S; Zhu Yingting; Narayan Satya T; Shakalya Kishore; Croce Kimiko Della; Georgiev Ivan G; Nagle Raymond B; Garewal Harinder; Von Hoff Daniel D; Mahadevan Daruka
Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer.
Cancer research 2009;69(5):1933-40.
2009: Henderson Meredith C; Shaw Yeng-Jeng Y; Wang Hong; Han Haiyong; Hurley Laurence H; Flynn Gary; Dorr Robert T; Von Hoff Daniel D
UA62784, a novel inhibitor of centromere protein E kinesin-like protein.
Molecular cancer therapeutics 2009;8(1):36-44.
2009: Hensley Martee L; Hagerty Karen L; Kewalramani Tarun; Green Daniel M; Meropol Neal J; Wasserman Todd H; Cohen Gary I; Emami Bahman; Gradishar William J; Mitchell R Brian; Thigpen J Tate; Trotti Andy; von Hoff Daniel; Schuchter Lynn M
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(1):127-45.
2009: Azorsa David O; Gonzales Irma M; Basu Gargi D; Choudhary Ashish; Arora Shilpi; Bisanz Kristen M; Kiefer Jeffrey A; Henderson Meredith C; Trent Jeffrey M; Von Hoff Daniel D; Mousses Spyro
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
Journal of translational medicine 2009;7():43.
2008: Warner Steven L; Muñoz Ruben M; Bearss David J; Grippo Paul; Han Haiyong; Von Hoff Daniel D
Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.
Pancreas 2008;37(3):e39-44.
2008: Balagurunathan Yoganand; Morse David L; Hostetter Galen; Shanmugam Vijayalakshmi; Stafford Phillip; Shack Sonsoles; Pearson John; Trissal Maria; Demeure Michael J; Von Hoff Daniel D; Hruby Victor J; Gillies Robert J; Han Haiyong
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer.
Molecular cancer therapeutics 2008;7(9):3071-80.
2008: Dragovich Tomislav; Burris Howard; Loehrer Patrick; Von Hoff Daniel D; Chow Sherry; Stratton Steven; Green Sylvan; Obregon Yrma; Alvarez Irene; Gordon Michael
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
American journal of clinical oncology 2008;31(2):157-62.
2008: Warner Steven L; Stephens Bret J; Von Hoff Daniel D
Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer.
Current oncology reports 2008;10(2):122-9.
2008: Baker Amanda F; Koh Mei Y; Williams Ryan R; James Brian; Wang Huamin; Tate Wendy R; Gallegos Alfred; Von Hoff Daniel D; Han Haiyong; Powis Garth
Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer.
Pancreas 2008;36(2):178-86.
2008: Stephan Elizabeth A; Chung Tae-Hoon; Grant Clive S; Kim Seungchan; Von Hoff Daniel D; Trent Jeffrey M; Demeure Michael J
Adrenocortical carcinoma survival rates correlated to genomic copy number variants.
Molecular cancer therapeutics 2008;7(2):425-31.
2008: Wiedenmann Bertram; Malfertheiner Peter; Friess Helmut; Ritch Paul; Arseneau James; Mantovani Giovanni; Caprioni Francesco; Van Cutsem Eric; Richel Dirk; DeWitte Mark; Qi Ming; Robinson Don; Zhong Bob; De Boer Carla; Lu J D; Prabhakar Uma; Corringham Robert; Von Hoff Daniel
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
The journal of supportive oncology 2008;6(1):18-25.
2008: Stephens Bret; Han Haiyong; Hostetter Galen; Demeure Michael J; Von Hoff Daniel D
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells.
Molecular cancer therapeutics 2008;7(1):202-10.
2008: Von Hoff Daniel D; Kuhn John G; Burris Howard A; Miller Larry J
Does intraosseous equal intravenous? A pharmacokinetic study.
The American journal of emergency medicine 2008;26(1):31-8.
2007: Sonpavde Guru; Aparicio Ana; Guttierez Israel; Boehm Kristi A; Hutson Thomas E; Berry William R; Asmar Lina; von Hoff Daniel D
Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.
Clinical genitourinary cancer 2007;5(7):457-9.
2007: Dragovich Tomislav; Huberman Mark; Von Hoff Daniel D; Rowinsky Eric K; Nadler Paul; Wood Debra; Hamilton Marta; Hage George; Wolf Julie; Patnaik Amita
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Cancer chemotherapy and pharmacology 2007;60(2):295-303.
2007: Zhu Ming; Gokhale Vijay M; Szabo Lajos; Munoz Ruben M; Baek Hyounggee; Bashyam Sridevi; Hurley Laurence H; Von Hoff Daniel D; Han Haiyong
Identification of a novel inhibitor of urokinase-type plasminogen activator.
Molecular cancer therapeutics 2007;6(4):1348-56.
2007: Mahadevan Daruka; Von Hoff Daniel D
Tumor-stroma interactions in pancreatic ductal adenocarcinoma.
Molecular cancer therapeutics 2007;6(4):1186-97.
2006: Dragovich Tomislav; Mendelson David; Kurtin Sandra; Richardson Kelly; Von Hoff Daniel; Hoos Axel
A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Cancer chemotherapy and pharmacology 2006;58(6):759-64.
2006: Lorenzi Philip L; Reinhold William C; Rudelius Martina; Gunsior Michele; Shankavaram Uma; Bussey Kimberly J; Scherf Uwe; Eichler Gabriel S; Martin Scott E; Chin Koei; Gray Joe W; Kohn Elise C; Horak Ivan D; Von Hoff Daniel D; Raffeld Mark; Goldsmith Paul K; Caplen Natasha J; Weinstein John N
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.
Molecular cancer therapeutics 2006;5(11):2613-23.
2006: Warner Steven L; Munoz Ruben M; Stafford Phillip; Koller Erich; Hurley Laurence H; Von Hoff Daniel D; Han Haiyong
Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells.
Molecular cancer therapeutics 2006;5(10):2450-8.
2006: Wang Hong; Han Haiyong; Von Hoff Daniel D
Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.
Cancer research 2006;66(19):9722-30.
2006: Garland Linda L; Taylor Charles; Pilkington Deborah L; Cohen Jan L; Von Hoff Daniel D
A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5182-9.
2006: Han Haiyong; Von Hoff Daniel D
Aurora sheds light on head and neck squamous cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5003-4.
2006: Wang Hong; Han Haiyong; Mousses Spyro; Von Hoff Daniel D
Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.
Seminars in oncology 2006;33(4):513-20.
2006: Hurley Laurence H; Von Hoff Daniel D; Siddiqui-Jain Adam; Yang Danzhou
Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element.
Seminars in oncology 2006;33(4):498-512.
2006: Warner Steven L; Gray Phillip J; Von Hoff Daniel D
Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
Seminars in oncology 2006;33(4):436-48.
2006: Warner Steven L; Bashyam Sridevi; Vankayalapati Hariprasad; Bearss David J; Han Haiyong; Mahadevan Daruka; Von Hoff Daniel D; Hurley Laurence H
Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.
Molecular cancer therapeutics 2006;5(7):1764-73.
2006: Tolcher Anthony W; Hao Desiree; de Bono Johann; Miller Alex; Patnaik Amita; Hammond Lisa A; Smetzer Leslie; Van Wart Hood Jill; Merritt James; Rowinsky Eric K; Takimoto Chris; Von Hoff Dan; Eckhardt S Gail
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(13):2052-8.
2006: Von Hoff Daniel D
What's new in pancreatic cancer treatment pipeline?
Best practice & research. Clinical gastroenterology 2006;20(2):315-26.
2005: Stephens Bret J; Han Haiyong; Gokhale Vijay; Von Hoff Daniel D
PRL phosphatases as potential molecular targets in cancer.
Molecular cancer therapeutics 2005;4(11):1653-61.
2005: Nyman David W; Campbell Kimberley J; Hersh Evan; Long Kristen; Richardson Kelly; Trieu Vuong; Desai Neil; Hawkins Michael J; Von Hoff Daniel D
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):7785-93.
2005: Oettle H; Richards D; Ramanathan R K; van Laethem J L; Peeters M; Fuchs M; Zimmermann A; John W; Von Hoff D; Arning M; Kindler H L
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(10):1639-45.
2005: Garland Linda; Gitlitz Barbara; Ebbinghaus Scot; Pan Henry; de Haan Hans; Puri Raj K; Von Hoff Daniel; Figlin Robert
Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(4):376-81.
2005: Lansky Ephraim Philip; Von Hoff Daniel D
Complex and simple.
Leukemia research 2005;29(6):601-2.
2005: O'Shaughnessy Joyce A; Vukelja Svetislava J; Holmes Frankie Ann; Savin Michael; Jones Monte; Royall Donald; George Martine; Von Hoff Daniel
Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.
Clinical breast cancer 2005;5(6):439-46.
2004: Manikumar Govindarajan; Wadkins Randy M; Bearss David; Von Hoff Daniel D; Wani Mansukhlal C; Wall Monroe E
Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.
Bioorganic & medicinal chemistry letters 2004;14(21):5377-81.
2004: Wadkins Randy M; Bearss David; Manikumar Govindarajan; Wani Mansukhlal C; Wall Monroe E; Von Hoff Daniel D
Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.
Cancer research 2004;64(18):6679-83.
2004: Schrag Deborah; Garewal Harinder S; Burstein Harold J; Samson David J; Von Hoff Daniel D; Somerfield Mark R;
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(17):3631-8.
2004: Wadkins Randy M; Bearss David; Manikumar Govindarajan; Wani Mansukhlal C; Wall Monroe E; Von Hoff Daniel D
Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity.
Current medicinal chemistry. Anti-cancer agents 2004;4(4):327-34.
2004: Gray Phillip J; Bearss David J; Han Haiyong; Nagle Raymond; Tsao Ming-Sound; Dean Nicholas; Von Hoff Daniel D
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.
Molecular cancer therapeutics 2004;3(5):641-6.
2004: Van Cutsem E; van de Velde H; Karasek P; Oettle H; Vervenne W L; Szawlowski A; Schoffski P; Post S; Verslype C; Neumann H; Safran H; Humblet Y; Perez Ruixo J; Ma Y; Von Hoff D
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1430-8.
2004: Rojanala Sangeeta; Han Haiyong; Muñoz Rubén M; Browne Walden; Nagle Raymond; Von Hoff Daniel D; Bearss David J
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.
Molecular cancer therapeutics 2004;3(4):451-7.
2004: Hammond Lisa A; Eckardt John R; Kuhn John G; Gerson Stanton L; Johnson Tom; Smith Lon; Drengler Ronald L; Campbell Elizabeth; Weiss Geoffrey R; Von Hoff Daniel D; Rowinsky Eric K
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1645-56.
2003: Forouzesh Bahram; Takimoto Chris H; Goetz Andrew; Diab Sami; Hammond Lisa A; Smetzer Leslie; Schwartz Garry; Gazak Robert; Callaghan John T; Von Hoff Daniel D; Rowinsky Eric K
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5540-9.
2003: Warner Steven L; Bearss David J; Han Haiyong; Von Hoff Daniel D
Targeting Aurora-2 kinase in cancer.
Molecular cancer therapeutics 2003;2(6):589-95.
2003: Schwartz G H; Patnaik A; Hammond L A; Rizzo J; Berg K; Von Hoff D D; Rowinsky E K
A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(5):775-82.
2003: Vankayalapati Hariprasad; Bearss David J; Saldanha José W; Muñoz Rubén M; Rojanala Sangeeta; Von Hoff Daniel D; Mahadevan Daruka
Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design.
Molecular cancer therapeutics 2003;2(3):283-94.
2003: Nishioka David; Marcell Vanessa; Cunningham Meghan; Khan Merium; Von Hoff Daniel D; Izbicka Elzbieta
The use of early sea urchin embryos in anticancer drug testing.
Methods in molecular medicine 2003;85():265-76.
2002: Von Hoff Daniel D
Translational research: stop, look, listen--if you expect to grow up tall.
Cancer biology & therapy 2002;1(6):718-20.
2002: Von Hoff Daniel D; Bearss David
New drugs for patients with pancreatic cancer.
Current opinion in oncology 2002;14(6):621-7.
2002: Hao Desirée; Rizzo Jinee D; Stringer Stephanie; Moore Rodney V; Marty Jennifer; Dexter Daniel L; Mangold Gina L; Camden James B; Von Hoff Daniel D; Weitman Steven D
Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642).
Investigational new drugs 2002;20(3):261-70.
2002: Siu Lillian L; Rowinsky Eric K; Hammond Lisa A; Weiss Geoffrey R; Hidalgo Manuel; Clark Gary M; Moczygemba Judy; Choi Les; Linnartz Ron; Barbet Nicholas C; Sklenar Ivo T; Capdeville Renaud; Gan Gregory; Porter Carl W; Von Hoff Daniel D; Eckhardt S Gail
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2157-66.
2002: Grand Cory L; Han Haiyong; Muñoz Rubén M; Weitman Steve; Von Hoff Daniel D; Hurley Laurence H; Bearss David J
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.
Molecular cancer therapeutics 2002;1(8):565-73.
2002: Han Haiyong; Bearss David J; Browne L Walden; Calaluce Robert; Nagle Raymond B; Von Hoff Daniel D
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.
Cancer research 2002;62(10):2890-6.
2002: Wang Weixin; Waters Stephen J; MacDonald John R; Roth Caleb; Shentu Shujun; Freeman James; Von Hoff Daniel D; Miller Alexander R
Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases.
Anticancer research 2002;22(2A):559-64.
2002: O'Shaughnessy Joyce A; Kelloff Gary J; Gordon Gary B; Dannenberg Andrew J; Hong Waun Ki; Fabian Carol J; Sigman Caroline C; Bertagnolli Monica M; Stratton Steven P; Lam Stephen; Nelson William G; Meyskens Frank L; Alberts David S; Follen Michele; Rustgi Anil K; Papadimitrakopoulou Vali; Scardino Peter T; Gazdar Adi F; Wattenberg Lee W; Sporn Michael B; Sakr Wael A; Lippman Scott M; Von Hoff Daniel D
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(2):314-46.
2002: Petit T; Davidson K K; Cerna C; Lawrence R A; Von Hoff D D; Heise C; Kirn D; Izbicka E
Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status.
Anti-cancer drugs 2002;13(1):47-50.
2002: Villalona-Calero Miguel A; Eckhardt S Gail; Weiss Geoffrey; Hidalgo Manuel; Beijnen Jos H; van Kesteren Charlotte; Rosing Hilde; Campbell Elizabeth; Kraynak Maura; Lopez-Lazaro Luis; Guzman Cecilia; Von Hoff Daniel D; Jimeno Jose; Rowinsky Eric K
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):75-85.
2001: Duan W; Rangan A; Vankayalapati H; Kim M Y; Zeng Q; Sun D; Han H; Fedoroff O Y; Nishioka D; Rha S Y; Izbicka E; Von Hoff D D; Hurley L H
Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects.
Molecular cancer therapeutics 2001;1(2):103-20.
2001: Rothenberg M L; Kuhn J G; Schaaf L J; Rodriguez G I; Eckhardt S G; Villalona-Calero M A; Rinaldi D A; Hammond L A; Hodges S; Sharma A; Elfring G L; Petit R G; Locker P K; Miller L L; von Hoff D D
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(11):1631-41.
2001: Schwartz G; Johnson T R; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker J A; Von Hoff D D; Rowinsky E K
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1901-11.
2001: Hidalgo M; Siu L L; Nemunaitis J; Rizzo J; Hammond L A; Takimoto C; Eckhardt S G; Tolcher A; Britten C D; Denis L; Ferrante K; Von Hoff D D; Silberman S; Rowinsky E K
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3267-79.
2001: Wang W; Waters S J; MacDonald J R; Von Hoff D D; Strodel W E; Miller A R
Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells.
Anticancer research 2001;21(3B):1789-94.
2001: Villalona-Calero M A; Blum J L; Jones S E; Diab S; Elledge R; Khoury P; Von Hoff D; Kraynak M; Moczygemba J; Kromelis P; Griffin T; Rowinsky E K
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):605-14.
2001: Hammond L A; Davidson K; Lawrence R; Camden J B; Von Hoff D D; Weitman S; Izbicka E
Exploring the mechanisms of action of FB642 at the cellular level.
Journal of cancer research and clinical oncology 2001;127(5):301-13.
2001: Raymond E; Faivre S; Weiss G; McGill J; Davidson K; Izbicka E; Kuhn J G; Allred C; Clark G M; Von Hoff D D
Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1171-80.
2001: Williams J I; Weitman S; Gonzalez C M; Jundt C H; Marty J; Stringer S D; Holroyd K J; Mclane M P; Chen Q; Zasloff M; Von Hoff D D
Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):724-33.
2001: Petit T; Davidson K K; Lawrence R A; von Hoff D D; Izbicka E
Neuropeptide receptor status in human tumor cell lines.
Anti-cancer drugs 2001;12(2):133-6.
2001: Villalona-Calero M A; Eder J P; Toppmeyer D L; Allen L F; Fram R; Velagapudi R; Myers M; Amato A; Kagen-Hallet K; Razvillas B; Kufe D W; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):857-69.
2000: Bearss D J; Hurley L H; Von Hoff D D
Telomere maintenance mechanisms as a target for drug development.
Oncogene 2000;19(56):6632-41.
2000: Eckhardt S G; Baker S D; Britten C D; Hidalgo M; Siu L; Hammond L A; Villalona-Calero M A; Felton S; Drengler R; Kuhn J G; Clark G M; Smith S L; MacDonald J R; Smith C; Moczygemba J; Weitman S; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(24):4086-97.
2000: Patnaik A; Rowinsky E K; Tammara B K; Hidalgo M; Drengler R L; Garner A M; Siu L L; Hammond L A; Felton S A; Mallikaarjun S; Von Hoff D D; Eckhardt S G
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3974-85.
2000: Hammond L A; Hilsenbeck S G; Eckhardt S G; Marty J; Mangold G; MacDonald J R; Rowinsky E K; Von Hoff D D; Weitman S
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2430-6.
2000: Rowinsky E K; Johnson T R; Geyer C E; Hammond L A; Eckhardt S G; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff D D; De Jager R L
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(17):3151-63.
2000: Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald J R; Waters S J; Von Hoff D
MGI 114: augmentation of antitumor activity when combined with topotecan.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2000;22(4):306-14.
2000: Raymond E; Soria J C; Izbicka E; Boussin F; Hurley L; Von Hoff D D
DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs.
Investigational new drugs 2000;18(2):123-37.
2000: Soda H; Raymond E; Sharma S; Lawrence R; Davidson K; Oka M; Kohno S; Izbicka E; Von Hoff D D
Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro.
The Prostate 2000;43(3):161-8.
2000: Weitman S; Marty J; Jolivet J; Locas C; Von Hoff D D
The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1574-8.
2000: Tolcher A W; Aylesworth C; Rizzo J; Izbicka E; Campbell E; Kuhn J; Weiss G; Von Hoff D D; Rowinsky E K
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(3):333-8.
2000: Rha S Y; Izbicka E; Lawrence R; Davidson K; Sun D; Moyer M P; Roodman G D; Hurley L; Von Hoff D
Effect of telomere and telomerase interactive agents on human tumor and normal cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):987-93.
2000: Ganly I; Kirn D; Eckhardt G; Rodriguez G I; Soutar D S; Otto R; Robertson A G; Park O; Gulley M L; Heise C; Von Hoff D D; Kaye S B;
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):798-806.
2000: Hurley L H; Wheelhouse R T; Sun D; Kerwin S M; Salazar M; Fedoroff O Y; Han F X; Han H; Izbicka E; Von Hoff D D
G-quadruplexes as targets for drug design.
Pharmacology & therapeutics 2000;85(3):141-58.
2000: Vladu B; Woynarowski J M; Manikumar G; Wani M C; Wall M E; Von Hoff D D; Wadkins R M
7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents.
Molecular pharmacology 2000;57(2):243-51.
2000: Britten C D; Rowinsky E K; Baker S D; Weiss G R; Smith L; Stephenson J; Rothenberg M; Smetzer L; Cramer J; Collins W; Von Hoff D D; Eckhardt S G
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):42-9.
2000: Monsky W L; Heddens D K; Clark G M; Von Hoff D D; Coltman C A; Dorr R T; Alberts D S
Comparison of young clinical investigators' accuracy and reproducibility when measuring pulmonary and skin surface nodules using a circumferential measurement versus a standard caliper measurement: American Association for Cancer Research/American Society of Clinical Oncology Clinical Trials Workshop.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(2):437-44.
2000: Rowinsky E K; Humphrey R; Hammond L A; Aylesworth C; Smetzer L; Hidalgo M; Morrow M; Smith L; Garner A; Sorensen J M; Von Hoff D D; Eckhardt S G
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):178-86.
2000: Hidalgo M; Villalona-Calero M A; Eckhardt S G; Drengler R L; Rodriguez G; Hammond L A; Diab S G; Weiss G; Garner A M; Campbell E; Davidson K; Louie A; O'Neil J D; von Borstel R; Von Hoff D D; Rowinsky E K
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):167-77.
1999: Del Poeta M; Chen S F; Von Hoff D; Dykstra C C; Wani M C; Manikumar G; Heitman J; Wall M E; Perfect J R
Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.
Antimicrobial agents and chemotherapy 1999;43(12):2862-8.
1999: Villalona-Calero M A; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt S G; Drengler R; Simmons C; Santabarbara P; Von Hoff D D; Rowinsky E K
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3369-78.
1999: Rowinsky E K; Windle J J; Von Hoff D D
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3631-52.
1999: Nemunaitis J; Holmlund J T; Kraynak M; Richards D; Bruce J; Ognoskie N; Kwoh T J; Geary R; Dorr A; Von Hoff D; Eckhardt S G
Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3586-95.
1999: Hidalgo M; Izbicka E; Eckhardt S G; MacDonald J R; Cerna C; Gomez L; Rowinsky E K; Weitman S D; Von Hoff D D
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Anti-cancer drugs 1999;10(9):837-44.
1999: Fracasso P M; Tan B R; Grieff M; Stephenson J; Liapis H; Umbeck N L; Von Hoff D D; Rowinsky E K
Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma.
Journal of the National Cancer Institute 1999;91(20):1779-80.
1999: Hensley M L; Schuchter L M; Lindley C; Meropol N J; Cohen G I; Broder G; Gradishar W J; Green D M; Langdon R J; Mitchell R B; Negrin R; Szatrowski T P; Thigpen J T; Von Hoff D; Wasserman T H; Winer E P; Pfister D G
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(10):3333-55.
1999: Izbicka E; Nishioka D; Marcell V; Raymond E; Davidson K K; Lawrence R A; Wheelhouse R T; Hurley L H; Wu R S; Von Hoff D D
Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos.
Anti-cancer drug design 1999;14(4):355-65.
1999: Hammond L A; Eckardt J R; Baker S D; Eckhardt S G; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss G R; Rinaldi D A; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2604-13.
1999: Lawrence R A; Izbicka E; De Jager R L; Tohgo A; Clark G M; Weitman S D; Rowinsky E K; Von Hoff D D
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.
Anti-cancer drugs 1999;10(7):655-61.
1999: Britten C D; Rowinsky E K; Baker S D; Agarwala S S; Eckardt J R; Barrington R; Diab S G; Hammond L A; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff D D; Eckhardt S G
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1629-37.
1999: Raymond E; Sun D; Izbicka E; Mangold G; Silvas E; Windle B; Sharma S; Soda H; Laurence R; Davidson K; Von Hoff D D
A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay.
British journal of cancer 1999;80(9):1332-41.
1999: Wadkins R M; Potter P M; Vladu B; Marty J; Mangold G; Weitman S; Manikumar G; Wani M C; Wall M E; Von Hoff D D
Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.
Cancer research 1999;59(14):3424-8.
1999: Petit T; Davidson K; Izbicka E; Von Hoff D D
Elimination of extrachromosomal c-myc genes by hydroxyurea induces apoptosis.
Apoptosis : an international journal on programmed cell death 1999;4(3):163-7.
1999: Villalona-Calero M A; Weiss G R; Burris H A; Kraynak M; Rodrigues G; Drengler R L; Eckhardt S G; Reigner B; Moczygemba J; Burger H U; Griffin T; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1915-25.
1999: Eckhardt S G; Rizzo J; Sweeney K R; Cropp G; Baker S D; Kraynak M A; Kuhn J G; Villalona-Calero M A; Hammond L; Weiss G; Thurman A; Smith L; Drengler R; Eckardt J R; Moczygemba J; Hannah A L; Von Hoff D D; Rowinsky E K
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(4):1095-104.
1999: Hidalgo M; Rinaldi D; Medina G; Griffin T; Turner J; Von Hoff D D
A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia.
Anti-cancer drugs 1999;10(4):393-5.
1999: Petit T; Izbicka E; Lawrence R A; Bishop W R; Weitman S; Von Hoff D D
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):449-53.
1999: Izbicka E; Davidson K; Lawrence R; Cote R; MacDonald J R; Von Hoff D D
Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression.
Anticancer research 1999;19(2A):1299-307.
1999: Izbicka E; Davidson K K; Lawrence R A; MacDonald J R; Von Hoff D D
5,6-Dihydro-5'-azacytidine (DHAC) affects estrogen sensitivity in estrogen-refractory human breast carcinoma cell lines.
Anticancer research 1999;19(2A):1293-8.
1999: Izbicka E; MacDonald J R; Davidson K; Lawrence R A; Gomez L; Von Hoff D D
5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells.
Anticancer research 1999;19(2A):1285-91.
1999: Petit T; Izbicka E; Lawrence R A; Nalin C; Weitman S D; Von Hoff D D
Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units.
Anti-cancer drugs 1999;10(3):309-15.
1999: Diab S G; Hilsenbeck S G; Izbicka E; Weitman S D; Von Hoff D D
Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system.
Anti-cancer drugs 1999;10(3):303-7.
1999: Hidalgo M; Izbicka E; Cerna C; Gomez L; Rowinsky E K; Weitman S D; Von Hoff D D
Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay.
Anti-cancer drugs 1999;10(3):295-302.
1999: Sun D; Lopez-Guajardo C C; Quada J; Hurley L H; Von Hoff D D
Regulation of catalytic activity and processivity of human telomerase.
Biochemistry 1999;38(13):4037-44.
1999: Hilsenbeck S G; Von Hoff D D
Measure once or twice -- does it really matter?
Journal of the National Cancer Institute 1999;91(6):494-5.
1999: Britten C D; Hilsenbeck S G; Eckhardt S G; Marty J; Mangold G; MacDonald J R; Rowinsky E K; Von Hoff D D; Weitman S
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Cancer research 1999;59(5):1049-53.
1999: Petit T; Aylesworth C; Burris H; Ravdin P; Rodriguez G; Smith L; Peacock N; Smetzer L; Bellet R; Von Hoff D D; Rowinsky E K
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(2):223-9.
1999: Rothenberg M L; Cox J V; DeVore R F; Hainsworth J D; Pazdur R; Rivkin S E; Macdonald J S; Geyer C E; Sandbach J; Wolf D L; Mohrland J S; Elfring G L; Miller L L; Von Hoff D D
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Cancer 1999;85(4):786-95.
1999: Drengler R L; Kuhn J G; Schaaf L J; Rodriguez G I; Villalona-Calero M A; Hammond L A; Stephenson J A; Hodges S; Kraynak M A; Staton B A; Elfring G L; Locker P K; Miller L L; Von Hoff D D; Rothenberg M L
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):685-96.
1999: Diab S G; Baker S D; Joshi A; Burris H A; Cobb P W; Villalona-Calero M A; Eckhardt S G; Weiss G R; Rodriguez G I; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff D D; Rowinsky E K
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(2):299-308.
1999: Izbicka E; Wheelhouse R T; Raymond E; Davidson K K; Lawrence R A; Sun D; Windle B E; Hurley L H; Von Hoff D D
Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells.
Cancer research 1999;59(3):639-44.
1999: Soda H; Raymond E; Sharma S; Lawrence R; Cerna C; Gomez L; Schaub R; Von Hoff D D; Izbicka E
Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors.
Anti-cancer drugs 1999;10(1):97-101.
1999: Genre D; Viens P; Von Hoff D D; Clark G M
Patients who are receiving concomitant medications should not systematically be excluded from phase I studies.
Anti-cancer drugs 1999;10(1):1-7.
1999: Gerrits C J; Schellens J H; Burris H; Eckardt J R; Planting A S; van der Burg M E; Rodriguez G I; Loos W J; van Beurden V; Hudson I; Von Hoff D D; Verweij J
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):69-75.
1999: Rinaldi D A; Kuhn J G; Burris H A; Dorr F A; Rodriguez G; Eckhardt S G; Jones S; Woodworth J R; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff D D
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Cancer chemotherapy and pharmacology 1999;44(5):372-80.
1999: Britten C D; Izbicka E; Hilsenbeck S; Lawrence R; Davidson K; Cerna C; Gomez L; Rowinsky E K; Weitman S; Von Hoff D D
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.
Cancer chemotherapy and pharmacology 1999;44(2):105-10.
1999: Weitman S; Mangold G; Marty J; Dexter D; Hilsenbeck S; Rake J; Juniewicz P; Von Hoff D
Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft.
Cancer chemotherapy and pharmacology 1999;43(5):402-8.
1998: Sun D; Hurley L H; Von Hoff D D
Telomerase assay using biotinylated-primer extension and magnetic separation of the products.
BioTechniques 1998;25(6):1046-51.
1998: Hidalgo M; Rodriguez G; Kuhn J G; Brown T; Weiss G; MacGovren J P; Von Hoff D D; Rowinsky E K
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2763-70.
1998: Von Hoff D D
Promising new agents for treatment of patients with colorectal cancer.
Seminars in oncology 1998;25(5 Suppl 11):47-52.
1998: Valero V; Jones S E; Von Hoff D D; Booser D J; Mennel R G; Ravdin P M; Holmes F A; Rahman Z; Schottstaedt M W; Erban J K; Esparza-Guerra L; Earhart R H; Hortobagyi G N; Burris H A
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3362-8.
1998: Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff D D
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(9):981-7.
1998: Rowinsky E K; Smith L; Wang Y M; Chaturvedi P; Villalona M; Campbell E; Aylesworth C; Eckhardt S G; Hammond L; Kraynak M; Drengler R; Stephenson J; Harding M W; Von Hoff D D
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2964-76.
1998: Siu L L; Attardo G; Izbicka E; Lawrence R; Cerna C; Gomez L; Davidson K; Finkle C; Marsolais C; Rowinsky E K; Von Hoff D D
Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(8):885-91.
1998: Davidson K; Petit T; Izbicka E; Koester S; Von Hoff D D
Mitoguazone induces apoptosis via a p53-independent mechanism.
Anti-cancer drugs 1998;9(7):635-40.
1998: Von Hoff D D
Phase I trials of dexrazoxane and other potential applications for the agent.
Seminars in oncology 1998;25(4 Suppl 10):31-6.
1998: Rothenberg M L; Kuhn J G; Schaaf L J; Drengler R L; Eckhardt S G; Villalona-Calero M A; Hammond L; Miller L L; Petit R G; Rowinsky E K; Von Hoff D D
Alternative dosing schedules for irinotecan.
Oncology (Williston Park, N.Y.) 1998;12(8 Suppl 6):68-71.
1998: Villalona-Calero M A; Baker S D; Hammond L; Aylesworth C; Eckhardt S G; Kraynak M; Fram R; Fischkoff S; Velagapudi R; Toppmeyer D; Razvillas B; Jakimowicz K; Von Hoff D D; Rowinsky E
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2770-9.
1998: Sharma S; Raymond E; Soda H; Izbicka E; Davidson K; Lawrence R; Von Hoff D D
Dimethyl sulfoxide (DMSO) causes a reversible inhibition of telomerase activity in a Burkitt lymphoma cell line.
Leukemia research 1998;22(8):663-70.
1998: Rothenberg M L; Sharma A; Weiss G R; Villalona-Calero M A; Eckardt J R; Aylesworth C; Kraynak M A; Rinaldi D A; Rodriguez G I; Burris H A; Eckhardt S G; Stephens C D; Forral K; Nicol S J; Von Hoff D D
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(7):733-8.
1998: Gerrits C J; Burris H; Schellens J H; Planting A S; van den Burg M E; Rodriguez G I; van Beurden V; Loos W J; Hudson I; Fields S; Verweij J; von Hoff D D
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1030-5.
1998: Morgan A S; Sanderson P E; Borch R F; Tew K D; Niitsu Y; Takayama T; Von Hoff D D; Izbicka E; Mangold G; Paul C; Broberg U; Mannervik B; Henner W D; Kauvar L M
Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.
Cancer research 1998;58(12):2568-75.
1998: Hammond L A; Eckardt J R; Ganapathi R; Burris H A; Rodriguez G A; Eckhardt S G; Rothenberg M L; Weiss G R; Kuhn J G; Hodges S; Von Hoff D D; Rowinsky E K
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1459-67.
1998: Gerrits C J; Burris H; Schellens J H; Eckardt J R; Planting A S; van der Burg M E; Rodriguez G I; Loos W J; van Beurden V; Hudson I; Fields S; Von Hoff D D; Verweij J
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1153-8.
1998: Von Hoff D D
There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1079-86.
1998: Soda H; Raymond E; Sharma S; Lawrence R; Cerna C; Gomez L; Timony G A; Von Hoff D D; Izbicka E
Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units.
Anti-cancer drugs 1998;9(4):327-31.
1998: Raymond E; Lawrence R; Izbicka E; Faivre S; Von Hoff D D
Activity of oxaliplatin against human tumor colony-forming units.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(4):1021-9.
1998: Schilsky R L; Hohneker J; Ratain M J; Janisch L; Smetzer L; Lucas V S; Khor S P; Diasio R; Von Hoff D D; Burris H A
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(4):1450-7.
1998: Weitman S; Moore R; Barrera H; Cheung N K; Izbicka E; Von Hoff D D
In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 1998;20(2):136-9.
1998: Eckhardt S G; Baker S D; Eckardt J R; Burke T G; Warner D L; Kuhn J G; Rodriguez G; Fields S; Thurman A; Smith L; Rothenberg M L; White L; Wissel P; Kunka R; DePee S; Littlefield D; Burris H A; Von Hoff D D; Rowinsky E K
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):595-604.
1998: Rodriguez G I; Kuhn J G; Weiss G R; Hilsenbeck S G; Eckardt J R; Thurman A; Rinaldi D A; Hodges S; Von Hoff D D; Rowinsky E K
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.
Blood 1998;91(5):1533-41.
1998: Villalona-Calero M A; Eckardt J; Burris H; Kraynak M; Fields-Jones S; Bazan C; Lancaster J; Hander T; Goldblum R; Hammond L; Bari A; Drengler R; Rothenberg M; Hadovsky G; Von Hoff D D
A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(1):71-7.
1998: Weiss G R; Poggesi I; Rocchetti M; DeMaria D; Mooneyham T; Reilly D; Vitek L V; Whaley F; Patricia E; Von Hoff D D; O'Dwyer P
A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):53-9.
1998: Izbicka E; Dalton W S; Troyer D; Von Hoff D D
Expression of two multidrug resistance genes in human prostatic carcinomas.
Journal of the National Cancer Institute 1998;90(2):166-7.
1998: Izbicka E; Lawrence R; Davidson K; Rake J B; Von Hoff D D
Effects of SW 33377, SW 68210 and SW 71425 thioxanthones on in vitro colony formation of freshly explanted human tumor cells.
Investigational new drugs 1998;16(3):221-5.
1998: Siu L L; Von Hoff D D; Rephaeli A; Izbicka E; Cerna C; Gomez L; Rowinsky E K; Eckhardt S G
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.
Investigational new drugs 1998;16(2):113-9.
1998: Rodriguez G I; Kuhn J G; Weiss G; De La Cruz P; New P; Fields S M; Eckardt J R; Campbell L; Clark G M; Hilsenbeck S G; Von Hoff D D
A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion.
Investigational new drugs 1998;16(1):57-67.
1998: Peacock N W; Burris H A; Dieras V; Smith L; Rodriguez G I; Eckardt J R; Jones S F; Hardy J; Hohneker J; Bigley J; Von Hoff D D
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors.
Investigational new drugs 1998;16(1):37-43.
1998: Burris H A; Raymond E; Awada A; Kuhn J G; O'Rourke T J; Brentzel J; Lynch W; King S Y; Brown T D; Von Hoff D D
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.
Investigational new drugs 1998;16(1):19-27.
1998: Von Hoff D D; Goodwin A L; Garcia L
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
British journal of cancer 1998;78 Suppl 3():9-13.
1997: Raymond E; Faivre S; Dieras V; Von Hoff D
[Inhibition of telomeres and telomerase. Seeking for new anticancer drugs]
Bulletin du cancer 1997;84(12):1123-33.
1997: Sharma S; Raymond E; Soda H; Sun D; Hilsenbeck S G; Sharma A; Izbicka E; Windle B; Von Hoff D D
Preclinical and clinical strategies for development of telomerase and telomere inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(11):1063-74.
1997: Raymond E; Izbicka E; Soda H; Gerson S L; Dugan M; Von Hoff D D
Activity of temozolomide against human tumor colony-forming units.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(10):1769-74.
1997: Raymond E; Burris H A; Rowinsky E K; Eckardt J R; Rodriguez G; Smith L; Weiss G; Von Hoff D D
Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):1003-8.
1997: Sharma S; Raymond E; Soda H; Von Hoff D D
Telomerase and telomere inhibitors in preclinical development.
Expert opinion on investigational drugs 1997;6(9):1179-85.
1997: Von Hoff D D
The taxoids: same roots, different drugs.
Seminars in oncology 1997;24(4 Suppl 13):S13-3-S13-10.
1997: Zhang X; Burt H M; Mangold G; Dexter D; Von Hoff D; Mayer L; Hunter W L
Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel.
Anti-cancer drugs 1997;8(7):696-701.
1997: Burris H A; Dieras V C; Tunca M; Earhart R H; Eckardt J R; Rodriguez G I; Shaffer D S; Fields S M; Campbell E; Schaaf L; Kasunic D; Von Hoff D D
Phase I study with the DNA sequence-specific agent adozelesin.
Anti-cancer drugs 1997;8(6):588-96.
1997: Rowinsky E; Smith L; Rodriguez G; White L; Drengler R; Von Hoff D; Peacock N; Aylesworth C; Burris H; Ravdin P; Bellet R
Docetaxel in combination with fluorouracil: study design and preliminary results.
Oncology (Williston Park, N.Y.) 1997;11(6 Suppl 6):33-5.
1997: Burris H A; Moore M J; Andersen J; Green M R; Rothenberg M L; Modiano M R; Cripps M C; Portenoy R K; Storniolo A M; Tarassoff P; Nelson R; Dorr F A; Stephens C D; Von Hoff D D
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2403-13.
1997: Heise C; Sampson-Johannes A; Williams A; McCormick F; Von Hoff D D; Kirn D H
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.
Nature medicine 1997;3(6):639-45.
1997: Raymond E; Hanauske A; Faivre S; Izbicka E; Clark G; Rowinsky E K; Von Hoff D D
Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units.
Anti-cancer drugs 1997;8(4):379-85.
1997: Izbicka E; Lawrence R; Cerna C; Von Hoff D D; Sanderson P E
Activity of TER286 against human tumor colony-forming units.
Anti-cancer drugs 1997;8(4):345-8.
1997: Levine A M; Tulpule A; Tessman D; Kaplan L; Giles F; Luskey B D; Scadden D T; Northfelt D W; Silverberg I; Wernz J; Espina B; Von Hoff D
Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1094-103.
1997: Creemers G J; Gerrits C J; Eckardt J R; Schellens J H; Burris H A; Planting A S; Rodriguez G I; Loos W J; Hudson I; Broom C; Verweij J; Von Hoff D D
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1087-93.
1997: MacDonald J R; Muscoplat C C; Dexter D L; Mangold G L; Chen S F; Kelner M J; McMorris T C; Von Hoff D D
Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
Cancer research 1997;57(2):279-83.
1997: Seal L; Von Hoff D; Lawrence R; Izbicka E; Jamison R M
An in vitro assessment of the antineoplastic potential of 2H-1,3-oxazine-2,6(3H)-dione (3-oxauracil), a novel pyrimidine.
Investigational new drugs 1997;15(4):289-93.
1997: Zhang X; Burt H M; Von Hoff D; Dexter D; Mangold G; Degen D; Oktaba A M; Hunter W L
An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel.
Cancer chemotherapy and pharmacology 1997;40(1):81-6.
1997: Jackson J K; Min W; Cruz T F; Cindric S; Arsenault L; Von Hoff D D; Degan D; Hunter W L; Burt H M
A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice.
British journal of cancer 1997;75(7):1014-20.
1996: Raymond E; Sun D; Chen S F; Windle B; Von Hoff D D
Agents that target telomerase and telomeres.
Current opinion in biotechnology 1996;7(6):583-91.
1996: Izquierdo M A; Degen D; Raymond E; Caron D; Ortiz V; Banks P; Von Hoff D D
Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein, on human tumor colony-forming units taken directly from patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1713-6.
1996: Von Hoff D D
Gemcitabine: a case study for clinical benefit.
Seminars in oncology 1996;23(5 Suppl 10):1-2.
1996: Eckhardt S G; Burris H A; Eckardt J R; Weiss G; Rodriguez G; Rothenberg M; Rinaldi D; Barrington R; Kuhn J G; Masuo K; Sudo K; Atsumi R; Oguma T; Higashi L; Fields S; Smetzer L; Von Hoff D D
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(5):491-6.
1996: Weiss G R; Shaffer D W; DeMoor C; Rinaldi D A; Rodriguez G I; Eckardt J R; Stephens C; Von Hoff D D
A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
Anti-cancer drugs 1996;7(4):402-9.
1996: Izquierdo M A; Degen D; Sypek J P; Von Hoff D D
Antiproliferative effects of interleukin-12 treatment on human tumor colony-forming units taken directly from patients.
Anti-cancer drugs 1996;7(3):275-80.
1996: Rothenberg M L; Moore M J; Cripps M C; Andersen J S; Portenoy R K; Burris H A; Green M R; Tarassoff P G; Brown T D; Casper E S; Storniolo A M; Von Hoff D D
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(4):347-53.
1996: Rothenberg M L; Eckardt J R; Kuhn J G; Burris H A; Nelson J; Hilsenbeck S G; Rodriguez G I; Thurman A M; Smith L S; Eckhardt S G; Weiss G R; Elfring G L; Rinaldi D A; Schaaf L J; Von Hoff D D
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1128-35.
1996: Von Hoff D D
"It feels better"--measuring clinical benefit.
European journal of cancer (Oxford, England : 1990) 1996;32A(2):376-7.
1996: Von Hoff D D
Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team.
Investigational new drugs 1996;14(3):265-70.
1996: von Hoff D
Future directions for clinical research with CPT-11 (irinotecan).
European journal of cancer (Oxford, England : 1990) 1996;32A Suppl 3():S9-12.
1996: Rizzo J; Levine A M; Weiss G R; Pearce T; Kraynak M; Mueck R; Smith S; Von Hoff D D; Kuhn J G
Pharmacokinetic profile of Mitoguazone (MGBG) in patients with AIDS related non-Hodgkin's lymphoma.
Investigational new drugs 1996;14(2):227-34.
1996: Woolley P V; Schultz C J; Rodriguez G I; Gams R A; Rowe K W; Dadey M L; Von Hoff D D; McPhillips J J
A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma.
Investigational new drugs 1996;14(2):219-22.
1995: Eckardt J; Eckhardt G; Villalona-Calero M; Drengler R; Von Hoff D
New anticancer agents in clinical development.
Oncology (Williston Park, N.Y.) 1995;9(12):1321-8; 1331; discussion 1332-4.
1995: Bedikian A Y; Weiss G R; Legha S S; Burris H A; Eckardt J R; Jenkins J; Eton O; Buzaid A C; Smetzer L; Von Hoff D D
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2895-9.
1995: Eckardt J; Eckhardt G; Villalona-Calero M; Drengler R; Von Hoff D
New anticancer agents in clinical development.
Oncology (Williston Park, N.Y.) 1995;9(11):1191-9.
1995: Izquierdo M A; Degen D; Myers L; Levitt D J; Von Hoff D D
Effects of the hematopoietic growth factors GM-CSF, IL-3, and IL-6 on human tumor colony-forming units taken directly from patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(9):927-32.
1995: Chen Y; Chen C F; Riley D J; Allred D C; Chen P L; Von Hoff D; Osborne C K; Lee W H
Aberrant subcellular localization of BRCA1 in breast cancer.
Science (New York, N.Y.) 1995;270(5237):789-91.
1995: Ritch P S; Keever C; Schiller J; Rivkin S; Witt P L; Grossberg S E; Truitt R L; Burris H; von Hoff D D; Vaickus L
Phase IA/IB evaluation of mammalian cell-derived glycosylated recombinant human interleukin (SIGOSIX) before and after cytotoxic chemotherapy.
Annals of the New York Academy of Sciences 1995;762():359-60.
1995: Zimmerman G C; Keeling J H; Burris H A; Cook G; Irvin R; Kuhn J; McCollough M L; Von Hoff D D
Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent.
Archives of dermatology 1995;131(2):202-6.
1995: Elledge R M; Clark G M; Hon J; Thant M; Belt R; Maguire Y P; Brown J; Bartels P; Von Hoff D D
Rapid in vitro assay for predicting response to fluorouracil in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):419-23.
1995: Van Den Berg C; Guan X Y; Von Hoff D; Jenkins R; Bittner; Griffin C; Kallioniemi O; Visakorpi; McGill; Herath J
DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(1):11-8.
1995: Ebrahim el-Zayat A A; Izquierdo M A; Clark G M; Von Hoff D D
Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro.
Investigational new drugs 1995;13(2):125-131.
1995: Van den Berg C; Von Hoff D D
Use of hydroxyurea to alter drug resistance of human tumor cells.
Cancer treatment and research 1995;78():95-114.
1995: Weiss G R; Kuhn J G; Rizzo J; Smith L S; Rodriguez G I; Eckardt J R; Burris H A; Fields S; VanDenBerg K; von Hoff D D
A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
Cancer chemotherapy and pharmacology 1995;35(5):397-402.
1995: Von Hoff D D
New agent development for women with breast cancer.
Cancer investigation 1995;13(3):341-4.
1995: Hanauske A R; Clark G M; Von Hoff D D
Adenocarcinoma of unknown primary: retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system.
Investigational new drugs 1995;13(1):43-9.
1995: Marshall M V; Carey K D; Von Hoff D D; Kuhn J G
Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons.
Investigational new drugs 1995;13(1):33-6.
1994: Cobb P W; Degen D R; Clark G M; Chen S F; Kuhn J G; Gross J L; Kirshenbaum M R; Sun J H; Burris H A; Von Hoff D D
Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units.
Journal of the National Cancer Institute 1994;86(19):1462-5.
1994: Van den Berg C L; McGill J R; Kuhn J G; Walsh J T; De La Cruz P S; Davidson K K; Wahl G M; Von Hoff D D
Pharmacokinetics of hydroxyurea in nude mice.
Anti-cancer drugs 1994;5(5):573-8.
1994: Burris H A; Awada A; Kuhn J G; Eckardt J R; Cobb P W; Rinaldi D A; Fields S; Smith L; Von Hoff D D
Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.
Anti-cancer drugs 1994;5(4):394-402.
1994: Eckhardt S G; Dai A; Davidson K K; Forseth B J; Wahl G M; Von Hoff D D
Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(14):6674-8.
1994: Von Hoff D D
MGBG: teaching an old drug new tricks.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):487-93.
1994: Martin K J; Chen S F; Clark G M; Degen D; Wajima M; Von Hoff D D; Kaddurah-Daouk R
Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells.
Journal of the National Cancer Institute 1994;86(8):608-13.
1994: Shimada Y; Rothenberg M; Hilsenbeck S G; Burris H A; Degen D; Von Hoff D D
Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Anti-cancer drugs 1994;5(2):202-6.
1994: Eckardt J R; Von Hoff D D
New drugs in clinical development in the United States.
Hematology/oncology clinics of North America 1994;8(2):305-32.
1994: Zimmerman G C; Keeling J H; Lowry M; Medina J; Von Hoff D D; Burris H A
Prevention of docetaxel-induced erythrodysesthesia with local hypothermia.
Journal of the National Cancer Institute 1994;86(7):557-8.
1994: Yee D; Jackson J G; Von Hoff D D; Ravdin P M
Case report: use of insulin-like growth factor-I gene expression to distinguish between breast and ovarian cancer.
The American journal of the medical sciences 1994;307(2):108-11.
1994: Eckardt J R; Burris H A; Kuhn J G; Bissery M C; Klink-Alakl M; Clark G M; Von Hoff D D
Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Journal of the National Cancer Institute 1994;86(1):30-3.
1994: O'Rourke T J; Brown T D; Havlin K; Kuhn J G; Craig J B; Burris H A; Satterlee W G; Tarassoff P G; Von Hoff D D
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.
European journal of cancer (Oxford, England : 1990) 1994;30A(3):417-8.
1994: Von Hoff D D; Burris H A; Eckardt J; Rothenberg M; Fields S M; Chen S F; Kuhn J G
Preclinical and phase I trials of topoisomerase I inhibitors.
Cancer chemotherapy and pharmacology 1994;34 Suppl():S41-5.
1994: Fuqua S A; Oesterreich S; Hilsenbeck S G; Von Hoff D D; Eckardt J; Osborne C K
Heat shock proteins and drug resistance.
Breast cancer research and treatment 1994;32(1):67-71.
1993: McGill J R; Beitzel B F; Nielsen J L; Walsh J T; Drabek S M; Meador R J; Von Hoff D D
Double minutes are frequently found in ovarian carcinomas.
Cancer genetics and cytogenetics 1993;71(2):125-31.
1993: Sarosdy M F; Hutzler D H; Yee D; von Hoff D D
In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity.
The Journal of urology 1993;150(6):1950-5.
1993: Hardin T C; Koeller J M; Kuhn J G; Roodman G D; Von Hoff D D
Nutritional parameters observed during 28-day infusion of recombinant human tumor necrosis factor-alpha.
JPEN. Journal of parenteral and enteral nutrition 1993;17(6):541-5.
1993: Sharma J; Von Hoff D D; Weiss G R
Salmonella arizonae peritonitis secondary to ingestion of rattlesnake capsules for gastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2288-9.
1993: Adkins D; Encarnacion C; Salzman D; Boldt D; Freytes C; Von Hoff D D; LeMaistre C F
Durable complete remission in a patient with refractory mediastinal non-seminomatous germ cell tumor after tandem high-dose chemotherapy and autologous bone marrow transplantation.
Bone marrow transplantation 1993;12(5):541-6.
1993: Vukelja S J; Baker W J; Burris H A; Keeling J H; Von Hoff D
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.
Journal of the National Cancer Institute 1993;85(17):1432-3.
1993: Albain K S; Crowley J J; Hutchins L; Gandara D; O'Bryan R M; Von Hoff D D; Griffin B; Livingston R B
Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base.
Cancer 1993;72(4):1184-91.
1993: Choy H; Rodriguez F F; Koester S; Hilsenbeck S; Von Hoff D D
Investigation of taxol as a potential radiation sensitizer.
Cancer 1993;71(11):3774-8.
1993: Marshall M V; Driskill-Kasprowicz G; Von Hoff D D; Hanauske A R
Stability of extrachromosomal DNA after different storage conditions.
BioTechniques 1993;14(5):737-9.
1993: Saiki J H; Stuckey W J; Athens J W; Tranum B L; Van Slyck E; Von Hoff D D
Mitoxantrone (dihydroxyanthracenedione) in acute leukemia. An evaluation of two treatment schedules by the Southwest Oncology Group.
Investigational new drugs 1993;11(2-3):197-200.
1993: Adkins D R; Irvin R; Kuhn J; Boldt D H; Roodman G D; Salzman D; Freytes C; Von Hoff D D; LeMaistre C F
A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.
Investigational new drugs 1993;11(2-3):169-79.
1993: Rodriguez G; Brown T D; Balis F M; Craig J B; Denham C A; Kuhn J G; Havlin K; Von Hoff D D
A phase I trial of trimetrexate (NSC352122) on a daily x 5 schedule in patients with refractory adult leukemia.
Anti-cancer drugs 1993;4(2):163-6.
1993: Thiebaut F; Hanauske A R; Von Hoff D D
Evidence for binding of extrachromosomal DNA sequences to nuclear matrix proteins in multidrug-resistant KB-V1 cells.
FEBS letters 1993;319(1-2):133-7.
1993: Rinaldi D A; Lippman S M; Burris H A; Chou C; Von Hoff D D; Hong W K
Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer.
Anti-cancer drugs 1993;4(1):33-6.
1993: el-Zayat A A; Degen D; Drabek S; Clark G M; Pettit G R; Von Hoff D D
In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub).
Anti-cancer drugs 1993;4(1):19-25.
1993: Nielsen J L; Walsh J T; Degen D R; Drabek S M; McGill J R; von Hoff D D
Evidence of gene amplification in the form of double minute chromosomes is frequently observed in lung cancer.
Cancer genetics and cytogenetics 1993;65(2):120-4.
1993: Voravud N; Lippman S M; Weber R S; Rodriquez G I; Yee D; Dimery I W; Earley C L; Von Hoff D D; Hong W K
Phase II trial of 13-cis-retinoic acid plus interferon-alpha in recurrent head and neck cancer.
Investigational new drugs 1993;11(1):57-60.
1993: Weiss G R; Brown T D; Kuhn J G; Von Hoff D D; Earhart R H; Adams W J; Brewer J E; Hosley J D; Kasunic D A
A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.
Investigational new drugs 1993;11(1):17-27.
1993: Marshall M V; Marshall M H; Degen D R; Roodman G D; Kuhn J G; Ross M E; Von Hoff D D
In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units.
Stem cells (Dayton, Ohio) 1993;11(1):62-9.
1993: Hanauske A R; Ross M; Degen D; Hilsenbeck S G; Von Hoff D D
In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):423-5.
1993: Krywicki R F; Figueroa J A; Jackson J G; Kozelsky T W; Shimasaki S; Von Hoff D D; Yee D
Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen.
European journal of cancer (Oxford, England : 1990) 1993;29A(14):2015-9.
1992: Von Hoff D D; McGill J; Davidson K; Forseth B; Atef Ebrahim el-Zayat A; Burris H
Preclinical leads for innovative uses for etoposide.
Seminars in oncology 1992;19(6 Suppl 13):10-3.
1992: VanDevanter D R; Yirdaw G; Do C; Tysseling K A; Drescher C A; Forseth B J; Von Hoff D D; McNutt M A
Preparation of uniform, intact DNA samples from resected tumor tissues for pulsed-field gel electrophoretic analyses.
BioTechniques 1992;13(6):884-7.
1992: Burris H A; Rothenberg M L; Kuhn J G; Von Hoff D D
Clinical trials with the topoisomerase I inhibitors.
Seminars in oncology 1992;19(6):663-9.
1992: Burris H A; Hanauske A R; Johnson R K; Marshall M H; Kuhn J G; Hilsenbeck S G; Von Hoff D D
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Journal of the National Cancer Institute 1992;84(23):1816-20.
1992: Melink T J; Clark G M; Von Hoff D D
The impact of phase I clinical trials on the quality of life of patients with cancer.
Anti-cancer drugs 1992;3(6):571-6.
1992: Hanauske A R; Degen D; Marshall M H; Trotta P P; Von Hoff D D
Lack of effects of recombinant human interleukin-4 on in vitro colony formation of freshly explanted human tumor cells.
Investigational new drugs 1992;10(4):269-73.
1992: Holzmayer T A; Hilsenbeck S; Von Hoff D D; Roninson I B
Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.
Journal of the National Cancer Institute 1992;84(19):1486-91.
1992: Von Hoff D D; McGill J R; Forseth B J; Davidson K K; Bradley T P; Van Devanter D R; Wahl G M
Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(17):8165-9.
1992: Wall J G; Burris H A; Von Hoff D D; Rodriguez G; Kneuper-Hall R; Shaffer D; O'Rourke T; Brown T; Weiss G; Clark G
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
Anti-cancer drugs 1992;3(4):337-45.
1992: McGill J R; Lalley P J; Leach R J; Johnson T J; Von Hoff D D
Chromosomal influence on hybrid cell proliferation.
Cell proliferation 1992;25(4):345-55.
1992: Haughey B H; von Hoff D D; Windle B E; Wahl G M; Mock P M
c-myc oncogene copy number in squamous carcinoma of the head and neck.
American journal of otolaryngology 1992;13(3):168-71.
1992: Von Hoff D D; Marshall M H; Heimbrook D C; Stirdivant S M; Ahern J D; Herbert W K; Maigetter R Z; Oliff A
Activity of a recombinant transforming growth factor-alpha-Pseudomonas exotoxin hybrid protein against primary human tumor colony-forming units.
Investigational new drugs 1992;10(1):17-22.
1992: Hanauske A R; Degen D; Marshall M H; Hilsenbeck S G; Grindey G B; Von Hoff D D
Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units.
Anti-cancer drugs 1992;3(2):143-6.
1992: Hanauske A R; Degen D; Marshall M H; Hilsenbeck S G; Banks P; Stuckey J; Leahy M; Von Hoff D D
Effects of recombinant human interleukin-1 alpha on clonogenic growth of primary human tumors in vitro.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;11(3):155-8.
1992: Hanauske A R; Degen D; Hilsenbeck S G; Bissery M C; Von Hoff D D
Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells.
Anti-cancer drugs 1992;3(2):121-4.
1992: Slichenmyer W J; LeMaistre C F; Von Hoff D D
Response of metastatic adenoid cystic carcinoma and Merkel cell tumor to high-dose melphalan with autologous bone marrow transplantation.
Investigational new drugs 1992;10(1):45-8.
1992: Harris G J; Clark G M; Von Hoff D D
Hispanic patients with head and neck cancer do not have a worse prognosis than Anglo-American patients.
Cancer 1992;69(4):1003-7.
1992: Hanauske A R; Degen D; Marshall M H; Hilsenbeck S G; McPhillips J J; Von Hoff D D
Preclinical activity of ilmofosine against human tumor colony forming units in vitro.
Anti-cancer drugs 1992;3(1):43-6.
1992: Bhuyan B K; Smith K S; Adams E G; Wallace T L; Von Hoff D D; Li L H
Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects.
Cancer chemotherapy and pharmacology 1992;30(5):348-54.
1991: Ravdin P M; Havlin K A; Marshall M V; Brown T D; Koeller J M; Kuhn J G; Rodriguez G; Von Hoff D D
A phase I clinical and pharmacokinetic trial of hepsulfam.
Cancer research 1991;51(23 Pt 1):6268-72.
1991: Slichenmyer W J; Von Hoff D D
Taxol: a new and effective anti-cancer drug.
Anti-cancer drugs 1991;2(6):519-30.
1991: Von Hoff D D; Waddelow T; Forseth B; Davidson K; Scott J; Wahl G
Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells.
Cancer research 1991;51(23 Pt 1):6273-9.
1991: Von Hoff D D
In vitro data supporting interferon plus cytotoxic agent combinations.
Seminars in oncology 1991;18(5 Suppl 7):58-61.
1991: Yee D; Morales F R; Hamilton T C; Von Hoff D D
Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer.
Cancer research 1991;51(19):5107-12.
1991: Gasparini G; Dal Fior S; Pozza F; Panizzoni G A; Favretto S; Von Hoff D D
Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.
Investigational new drugs 1991;9(3):245-52.
1991: Brown T; Havlin K; Weiss G; Cagnola J; Koeller J; Kuhn J; Rizzo J; Craig J; Phillips J; Von Hoff D
A phase I trial of taxol given by a 6-hour intravenous infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(7):1261-7.
1991: Von Hoff D D; Green S; Alberts D S; Stock-Novack D L; Surwit E A; Miller T P; Stephens R L
Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced endometrial cancer. A Southwest Oncology Group Study.
American journal of clinical oncology 1991;14(3):193-4.
1991: Von Hoff D D; Green S J; Neidhart J A; Fabian C; Budd T; Boyd J F; Osborne C K
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
Investigational new drugs 1991;9(1):87-8.
1991: Von Hoff D D; Turner J
Response rates, duration of response, and dose response effects in phase I studies of antineoplastics.
Investigational new drugs 1991;9(1):115-22.
1991: Benner S E; Wahl G M; Von Hoff D D
Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines.
Anti-cancer drugs 1991;2(1):11-25.
1991: Kish J A; Kopecky K; Samson M K; Von Hoff D D; Fletcher W S; Kempf R A; Muggia F M
Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study.
Investigational new drugs 1991;9(1):105-8.
1991: Von Hoff D D; Kronmal R; Salmon S E; Turner J; Green J B; Bonorris J S; Moorhead E L; Hynes H E; Pugh R E; Belt R J
A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer.
Cancer 1991;67(1):20-7.
1991: Havlin K A; Kuhn J G; Craig J B; Boldt D H; Weiss G R; Koeller J; Harman G; Schwartz R; Clark G N; Von Hoff D D
Phase I clinical and pharmacokinetic trial of flavone acetic acid.
Journal of the National Cancer Institute 1991;83(2):124-8.
1991: Von Hoff D D
Intraosseous infusions: an important but forgotten method of vascular access.
Cancer investigation 1991;9(5):521-8.
1991: Von Hoff D D
New mechanisms of gene amplification in drug resistance (the episome model).
Cancer treatment and research 1991;57():1-11.
1991: Van Nguyen M; Clark G M; Mascorro D; Von Hoff D D
In-vitro chemosensitivity testing of human gastric adenocarcinoma.
Cancer treatment and research 1991;55():133-42.
1990: Von Hoff D D; Kuhn J G; Havlin K A; Langevin A M; Brown T D; Weiss G R; Turner J N; Purvis J; Lucas V S; Bair K W
Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.
Cancer research 1990;50(23):7496-500.
1990: VanDevanter D R; Piaskowski V D; Casper J T; Douglass E C; Von Hoff D D
Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo.
Journal of the National Cancer Institute 1990;82(23):1815-21.
1990: Von Hoff D D; Fleming T R; Macdonald J S; Goodman P J; Van Damme J; Brown T D; O'Rourke T; Feun L G; Keppen M D
Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study.
Journal of biological response modifiers 1990;9(6):584-7.
1990: Dinesman A; Haughey B; Gates G A; Aufdemorte T; Von Hoff D D
Development of a new in vivo model for head and neck cancer.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1990;103(5 ( Pt 1)):766-74.
1990: Keaton M; Brown T; Craig J; Fries G; Harmon G; Zaloznik A; Orczyk G; Von Hoff D
Phase II study of carbetimer in non-small cell lung cancer.
Investigational new drugs 1990;8(4):385-6.
1990: Von Hoff D D; Metch B; Lucas J G; Balcerzak S P; Grunberg S M; Rivkin S E
Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.
Journal of interferon research 1990;10(5):531-4.
1990: Foulke R S; Marshall M H; Trotta P P; Von Hoff D D
In vitro assessment of the effects of granulocyte-macrophage colony-stimulating factor on primary human tumors and derived lines.
Cancer research 1990;50(19):6264-7.
1990: Fields S; Koeller J; Topper R L; Guritz G; Von Hoff D
Local soft tissue toxicity following cisplatin extravasation.
Journal of the National Cancer Institute 1990;82(20):1649-50.
1990: Von Hoff D D; Green S; Surwit E A; Hannigan E V; Alberts D S
Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer. A Southwest Oncology Group study.
American journal of clinical oncology 1990;13(5):433-5.
1990: Von Hoff D D
Phase I clinical trials with fludarabine phosphate.
Seminars in oncology 1990;17(5 Suppl 8):33-8.
1990: Mather F J; Simon R M; Clark G M; Von Hoff D D
A method for the evaluation of dose-toxicity relationships in clinical trials.
Statistics in medicine 1990;9(9):1117-8.
1990: Slichenmyer W J; Von Hoff D D
New natural products in cancer chemotherapy.
Journal of clinical pharmacology 1990;30(9):770-88.
1990: Noonan K E; Beck C; Holzmayer T A; Chin J E; Wunder J S; Andrulis I L; Gazdar A F; Willman C L; Griffith B; Von Hoff D D
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(18):7160-4.
1990: Von Hoff D D; Dahlberg S; Hartstock R J; Eyre H J
Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study.
Journal of the National Cancer Institute 1990;82(16):1353-5.
1990: Weiss R B; Donehower R C; Wiernik P H; Ohnuma T; Gralla R J; Trump D L; Baker J R; Van Echo D A; Von Hoff D D; Leyland-Jones B
Hypersensitivity reactions from taxol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1263-8.
1990: Von Hoff D D; Forseth B; Clare C N; Hansen K L; VanDevanter D
Double minutes arise from circular extrachromosomal DNA intermediates which integrate into chromosomal sites in human HL-60 leukemia cells.
The Journal of clinical investigation 1990;85(6):1887-95.
1990: Von Hoff D D; Goodman P J; Presant C A; Ruxer R L; MacDonald J S; Costanzi J J; Stephens R L; Vogel S J
A phase II trial of continuous infusion vinblastine in patients with gastric carcinoma. A Southwest Oncology Group study.
European journal of cancer (Oxford, England : 1990) 1990;26(3):405-7.
1990: Oishi N; Fleming T R; Laufman L; Ungerleider J S; Natale R B; Einstein A B; Von Hoff D D; Macdonald J S
VM-26 in colorectal carcinoma: a Southwest Oncology Group study.
Investigational new drugs 1990;8(1):93-5.
1990: Taylor S A; Fleming T; Von Hoff D D; McCracken J D; Bukowski R M; Talley R W; Natale R B; Guy J T; Samlowski W E; Costanzi J H
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group study.
Investigational new drugs 1990;8(1):77-80.
1990: Mattox D E; Von Hoff D D; Balcerzak S P
Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck.
Investigational new drugs 1990;8(1):105-7.
1990: Von Hoff D D
He's not going to talk about in vitro predictive assays again, is he?
Journal of the National Cancer Institute 1990;82(2):96-101.
1990: Von Hoff D D; Sandbach J F; Clark G M; Turner J N; Forseth B F; Piccart M J; Colombo N; Muggia F M
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician.
Journal of the National Cancer Institute 1990;82(2):110-6.
1990: Melink T J; Sarosy G; Hanauske A R; Phillips J L; Bayne J H; Grever M R; Jayaram H N; Von Hoff D D
Phase I trial and biochemical evaluation of tiazofurin administered on a weekly schedule.
Selective cancer therapeutics 1990;6(1):51-61.
1990: Brown T D; Havlin K A; Koeller J M; Kuhn J G; O'Rourke T J; Rodriguez G I; Weiss G R; Von Hoff D D
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1990;11():115-41.
1990: Von Hoff D D; Blumenstein B A; Pollock T W; Crawford E D; Weick J K; Guy J T; Eisenberger M; Fletcher W S; Natale R B
Methylglyoxal bis-guanylhydrazone in advanced bladder cancer.
European journal of cancer (Oxford, England : 1990) 1990;26(7):848-9.
1990: Rizzo J; Riley C; von Hoff D; Kuhn J; Phillips J; Brown T
Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics.
Journal of pharmaceutical and biomedical analysis 1990;8(2):159-64.
1990: Van Devanter D R; Von Hoff D D
Acid depurination after field inversion agarose gel electrophoresis reduces transfer of large DNA molecules.
Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society 1990;1(4):189-92.
1989: Weiss G R; Sarosy G A; Shenkenberg T D; Williams T; Clendeninn N J; Von Hoff D D; Woolley J L; Liao S H; Blum M R
A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).
European journal of cancer & clinical oncology 1989;25(12):1867-73.
1989: Sarosdy M F; Einhorn L H; Donohue J P; Von Hoff D D
Correlation of clonogenic growth with histologic diagnosis after resection of residual tissue following chemotherapy for nonseminomatous testis cancer.
Urology 1989;34(6):396-8.
1989: Lathan B; Kerkhoff K; Scheithauer W; Von Hoff D D; Diehl V
Homogeneous growth of tumor cell colonies in agar containing glass capillaries.
Anticancer research 1989;9(6):1897-902.
1989: Arteaga C L; Brown T D; Kuhn J G; Shen H S; O'Rourke T J; Beougher K; Brentzel H J; Von Hoff D D; Weiss G R
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Cancer research 1989;49(16):4648-53.
1989: Mather F J; Simon R M; Clark G M; Von Hoff D D
A method for the evaluation of dose-toxicity relationships in clinical trials.
Statistics in medicine 1989;8(7):813-23.
1989: Kuhn J G; Von Hoff D D; Hersh M; Melink T; Clark G M; Weiss G R; Coltman C A
Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion.
European journal of cancer & clinical oncology 1989;25(5):797-803.
1989: Wallen J W; Cate R L; Kiefer D M; Riemen M W; Martinez D; Hoffman R M; Donahoe P K; Von Hoff D D; Pepinsky B; Oliff A
Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Cancer research 1989;49(8):2005-11.
1989: Havlin K A; Kuhn J G; Myers J W; Ozols R F; Mattox D E; Clark G M; von Hoff D D
High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase II pilot study.
Cancer 1989;63(3):423-7.
1989: Harris G J; Tio F O; Von Hoff D D
Primary adrenal lymphoma.
Cancer 1989;63(4):799-803.
1989: Van Devanter D R; Trammell H M; Von Hoff D D
Simple construction of rubber-based agarose block molds for pulsed-field electrophoresis.
BioTechniques 1989;7(2):143-4.
1989: Dorr R T; Liddil J D; Von Hoff D D; Soble M; Osborne C K
Antitumor activity and murine pharmacokinetics of parenteral acronycine.
Cancer research 1989;49(2):340-4.
1989: Ruiz J C; Choi K H; von Hoff D D; Roninson I B; Wahl G M
Autonomously replicating episomes contain mdr1 genes in a multidrug-resistant human cell line.
Molecular and cellular biology 1989;9(1):109-15.
1989: Phillips J L; Schwartz R; Von Hoff D D
In vitro distribution of diacetyl didemnin B in human blood cells and plasma.
Cancer investigation 1989;7(2):123-8.
1989: Lathan B; Von Hoff D D; Clark G M; Elslager E E
Evaluation of an amsacrine analog in a human tumor cloning system.
Cancer chemotherapy and pharmacology 1989;24(4):230-2.
1989: Hanauske U; Hanauske A R; Clark G M; Tsen D; Buchok J; von Hoff D D
A new in vitro screening system for anticancer drugs for the treatment of non-small cell lung cancer.
Selective cancer therapeutics 1989;5(3):97-111.
1988: Von Hoff D D; Huong A M
Effect of recombinant interferon-beta ser on primary human tumor colony-forming units.
Journal of interferon research 1988;8(6):813-20.
1988: von Hoff D D
Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development.
Cancer metastasis reviews 1988;7(4):357-71.
1988: Lathan B; Diehl V; Clark G M; von Hoff D D
Cytotoxic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC 312887) in a human tumor cloning system.
European journal of cancer & clinical oncology 1988;24(12):1891-5.
1988: Dorr F A; Kuhn J G; Phillips J; von Hoff D D
Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide.
European journal of cancer & clinical oncology 1988;24(11):1699-706.
1988: McGuire W L; Kern D H; Von Hoff D D; Weisenthal L M
In vitro assays to predict drug sensitivity and drug resistance. A panel discussion.
Breast cancer research and treatment 1988;12(1):7-21.
1988: Arteaga C L; Hanauske A R; Clark G M; Osborne C K; Hazarika P; Pardue R L; Tio F; Von Hoff D D
Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis.
Cancer research 1988;48(17):5023-8.
1988: Von Hoff D D; Needham-VanDevanter D R; Yucel J; Windle B E; Wahl G M
Amplified human MYC oncogenes localized to replicating submicroscopic circular DNA molecules.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(13):4804-8.
1988: Arteaga C L; Tandon A K; Von Hoff D D; Osborne C K
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells.
Cancer research 1988;48(14):3898-904.
1988: Hanauske A R; Hanauske U; Buchok J; Von Hoff D D
Recombinant human transforming growth factor-alpha stimulates in vitro colony formation of fresh human tumor specimens.
International journal of cell cloning 1988;6(3):221-9.
1988: Hanauske A R; Arteaga C L; Clark G M; Buchok J; Marshall M; Hazarika P; Pardue R L; Von Hoff D D
Determination of transforming growth factor activity in effusions from cancer patients.
Cancer 1988;61(9):1832-7.
1988: Lippman S M; Kessler J F; Al-Sarraf M; Alberts D S; Itri L M; Mattox D; Von Hoff D D; Loescher L; Meyskens F L
Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial.
Investigational new drugs 1988;6(1):51-6.
1988: Carroll S M; DeRose M L; Gaudray P; Moore C M; Needham-Vandevanter D R; Von Hoff D D; Wahl G M
Double minute chromosomes can be produced from precursors derived from a chromosomal deletion.
Molecular and cellular biology 1988;8(4):1525-33.
1988: Von Hoff D D; Kronmal R; O'Toole R V; Surwit E A; Hutton J J; Alberts D S
Phase II study of fludarabine phosphate (NSC-312887) in patients with advanced ovarian cancer. A Southwest Oncology Group Study.
American journal of clinical oncology 1988;11(2):146-8.
1988: Pinelli A; Trivulzio S; Von Hoff D D; Monti D; Manitto P
Observations on the chemical structure and cytotoxic activity of marycin, a hematoporphyrin derivative.
Cancer letters 1988;38(3):257-69.
1988: Scheithauer W; Moyer M P; Clark G M; Von Hoff D D
Application of a new preclinical drug screening system for cancer of the large bowel.
Cancer chemotherapy and pharmacology 1988;21(1):31-4.
1988: Metelmann H R; Von Hoff D
[Anti-oncogram-assisted treatment planning in malignant melanoma]
Fortschritte der Kiefer- und Gesichts-Chirurgie 1988;33():168-70.
1988: Stein J; Strandjord S; Saarinen U; Warkentin P; Gerson S; Lazarus H; Von Hoff D; Coccia P; Cheung N K
In vitro treatment of autologous bone marrow for neuroblastoma patients with anti GD2 monoclonal antibody and human complement: a pilot study.
Progress in clinical and biological research 1988;271():237-48.
1988: Weiss G R; Arteaga C L; Brown T D; Craig J B; Harman G S; Havlin K A; Koeller J M; Kuhn J G; Von Hoff D D
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1988;10():85-116.
1988: Grever M R; Kopecky K J; Coltman C A; Files J C; Greenberg B R; Hutton J J; Talley R; Von Hoff D D; Balcerzak S P
Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
Nouvelle revue française d'hématologie 1988;30(5-6):457-9.
1987: Mercier R J; Neal G D; Mattox D E; Gates G A; Pomeroy T C; Von Hoff D D
Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck.
Cancer 1987;60(11):2609-12.
1987: Pinelli A; Trivulzio S; Von Hoff D D; Warfel L
Comparison of two methods to evaluate drug-cytotoxicity on tumor cell lines cultured in vitro.
Pharmacological research communications 1987;19(12):913-23.
1987: Arteaga C L; Forseth B J; Clark G M; Von Hoff D D
A radiometric method for evaluation of chemotherapy sensitivity: results of screening a panel of human breast cancer cell lines.
Cancer research 1987;47(23):6248-53.
1987: Harvey W H; Fleming T R; Von Hoff D D; Katterhagen J G; Coltman C A
Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study.
Cancer treatment reports 1987;71(12):1319-20.
1987: Weiss G B; Metch B; Von Hoff D D; Taylor S A; Saiers J H
Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study.
Cancer treatment reports 1987;71(12):1313-4.
1987: Arteaga C L; Kisner D L; Goodman A; von Hoff D D
Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system.
European journal of cancer & clinical oncology 1987;23(11):1621-6.
1987: Harvey W H; Fleming T R; Beltran G; Saiers J H; Oishi N; Von Hoff D D
Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group Study.
Cancer treatment reports 1987;71(11):1111-2.
1987: Lillis P K; Brown T D; Beougher K; Koeller J; Marcus S G; Von Hoff D D
Phase II trial of recombinant beta interferon in advanced colorectal cancer.
Cancer treatment reports 1987;71(10):965-7.
1987: Pinelli A; Trivulzio S; von Hoff D D; Warfel L E
Cytotoxic effects and physicochemical properties of marycin: a new hematoporphyrin derivative.
European journal of cancer & clinical oncology 1987;23(9):1289-96.
1987: Sebolt J S; Scavone S V; Pinter C D; Hamelehle K L; Von Hoff D D; Jackson R C
Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro.
Cancer research 1987;47(16):4299-304.
1987: Hanauske A R; Hanauske U; von Hoff D D
Recent improvements in the human tumor cloning assay for sensitivity testing of antineoplastic agents.
European journal of cancer & clinical oncology 1987;23(6):603-5.
1987: Mather F J; Simon R M; Clark G M; Von Hoff D D
Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies.
Cancer treatment reports 1987;71(6):609-13.
1987: Hanauske A R; Osborne C K; Chamness G C; Clark G M; Forseth B J; Buchok J B; Arteaga C L; Von Hoff D D
Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents.
European journal of cancer & clinical oncology 1987;23(5):545-51.
1987: Von Hoff D D
In vitro predictive testing: the sulfonamide era.
International journal of cell cloning 1987;5(3):179-90.
1987: Brown T D; Koeller J; Beougher K; Golando J; Bonnem E M; Spiegel R J; Von Hoff D D
A phase I clinical trial of recombinant DNA gamma interferon.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(5):790-8.
1987: Carroll S M; Gaudray P; De Rose M L; Emery J F; Meinkoth J L; Nakkim E; Subler M; Von Hoff D D; Wahl G M
Characterization of an episome produced in hamster cells that amplify a transfected CAD gene at high frequency: functional evidence for a mammalian replication origin.
Molecular and cellular biology 1987;7(5):1740-50.
1987: Balducci L; Blumenstein B; Von Hoff D D; Davis M; Hynes H E; Bukowski R M; Crawford E D
Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study.
Cancer treatment reports 1987;71(5):543-4.
1987: Hanauske U; Hanauske A R; Marshall M H; Muggia V A; Von Hoff D D
Biphasic effect of vanadium salts on in vitro tumor colony growth.
International journal of cell cloning 1987;5(2):170-8.
1987: Von Hoff D D
Whither carboplatin?--A replacement for or an alternative to cisplatin?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(2):169-71.
1987: Mamber S W; Mitulski J D; Hamelehle K L; French J C; Hokanson G C; Shillis J L; Leopold W R; Von Hoff D D; Tunac J B
Biological effects of acetomycin. I. Activity against tumor cells in vitro and in vivo.
The Journal of antibiotics 1987;40(1):73-6.
1987: Hanauske A R; Buchok J; Scheithauer W; Von Hoff D D
Human colon cancer cell lines secrete alpha TGF-like activity.
British journal of cancer 1987;55(1):57-9.
1987: Kuhn J G; Balmer C E; Ludden T M; Loesch D M; Von Hoff D D; Bender J F; Grillo-Lopez A J
Pharmacokinetics of ametantrone acetate (NSC-287513).
Cancer chemotherapy and pharmacology 1987;19(2):133-7.
1987: Weiss G R; Arteaga C L; Brown T D; Craig J B; Harman G S; Koeller J M; Kuhn J G; Von Hoff D D
New anticancer agents.
Cancer chemotherapy and biological response modifiers 1987;9():93-120.
1986: Scheithauer W; Clark G M; Salmon S E; Dorda W; Shoemaker R H; Von Hoff D D
Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man.
Cancer treatment reports 1986;70(12):1379-82.
1986: Merkel D E; Griffin N L; Kagan-Hallet K; Von Hoff D D
Central nervous system toxicity with fludarabine.
Cancer treatment reports 1986;70(12):1449-50.
1986: Von Hoff D D; Clark G M; Weiss G R; Marshall M H; Buchok J B; Knight W A; LeMaistre C F
Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(12):1827-34.
1986: Hanauske A R; Buchok J B; Pardue R L; Muggia V A; Von Hoff D D
Assessment of biological activity of linear alpha-transforming growth factor and monospecific antibodies to alpha-transforming growth factor and linear alpha-transforming growth factor.
Cancer research 1986;46(11):5567-70.
1986: Sarosy G A; Brown T D; Von Hoff D D; Spiegel R J; Golando J P; Beougher K L; Kuhn J G; Kisner D L
Phase I study of alpha 2-interferon plus doxorubicin in patients with solid tumors.
Cancer research 1986;46(10):5368-71.
1986: Von Hoff D D; Forseth B; Gonzales L
Culture and sensitivity testing of tumors.
Texas medicine 1986;82(9):32-5.
1986: Von Hoff D D; Sarosy G; Brown T D; Kuhn J G; Kisner D L
Rationale for and conduct of a phase I clinical trial with interferon alfa-2b plus doxorubicin.
Seminars in oncology 1986;13(3 Suppl 2):72-7.
1986: Hanauske A R; Von Hoff D D
The value of the human tumor cloning assay in ovarian cancer.
Clinical obstetrics and gynecology 1986;29(3):638-46.
1986: Von Hoff D D; Clark G M; Forseth B J; Cowan J D
Simultaneous in vitro drug sensitivity testing on tumors from different sites in the same patient.
Cancer 1986;58(5):1007-13.
1986: Weiss G R; Crowley J; Von Hoff D D; Taylor S A; Belt R J; Coltman C A; Hynes H E; Costanzi J J
Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: a Southwest Oncology Group Study.
Cancer treatment reports 1986;70(9):1123-4.
1986: Scheithauer W; Von Hoff D D; Clark G M; Shillis J L; Elslager E F
In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay.
European journal of cancer & clinical oncology 1986;22(8):921-6.
1986: Von Hoff D D; Forseth B J; Huong M; Buchok J B; Lathan B
Improved plating efficiencies for human tumors cloned in capillary tubes versus Petri dishes.
Cancer research 1986;46(8):4012-7.
1986: Shenkenberg T D; Von Hoff D D
Mitoxantrone: a new anticancer drug with significant clinical activity.
Annals of internal medicine 1986;105(1):67-81.
1986: Scheithauer W; Clark G M; Moyer M P; Von Hoff D D
New screening system for selection of anticancer drugs for treatment of human colorectal cancer.
Cancer research 1986;46(6):2703-8.
1986: Shenkenberg T D; Von Hoff D D
Possible mitoxantrone-induced amenorrhea.
Cancer treatment reports 1986;70(5):659-61.
1986: Dorr F A; Von Hoff D D; Kuhn J G; Schwartz R; Kisner D L
Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic.
Cancer research 1986;46(5):2562-5.
1986: Berdel W E; Von Hoff D D; Unger C; Schick H D; Fink U; Reichert A; Eibl H; Rastetter J
Ether lipid derivatives: antineoplastic activity in vitro and the structure-activity relationship.
Lipids 1986;21(4):301-4.
1986: Hilgers R D; Von Hoff D D; Stephens R L; Boutselis J G
Mitoxantrone and advanced squamous cell carcinoma of the cervix: a Southwest Oncology Group Study.
Cancer treatment reports 1986;70(4):527-8.
1986: Hersh M R; Linn W; Kuhn J G; Von Hoff D D
Electrocardiographic monitoring of patients receiving phase I cancer chemotherapy.
Cancer treatment reports 1986;70(3):349-52.
1986: Cheung N K; Von Hoff D D; Strandjord S E; Coccia P F
Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(3):363-9.
1986: Von Hoff D D; Forseth B J; Turner J N; Clark G M; Warfel L E
Selection of chemotherapy for patient treatment utilizing a radiometric versus a cloning system.
International journal of cell cloning 1986;4(1):16-26.
1986: Scheithauer W; Von Hoff D D; Forseth B; Cowan J D
Direct effects of the hypoxic cell sensitizer misonidazole on colony formation in a human tumor cloning assay.
Cancer drug delivery 1986;3(1):15-24.
1986: Harris G J; Von Hoff D D
Drug sensitivity testing of carcinoma of the gallbladder and biliary tree in a human tumor cloning assay.
Cancer drug delivery 1986;3(3):197-204.
1986: Harris G J; Turner J N; Von Hoff D D
Growth of carcinoma of the esophagus and gastroesophageal junction in a human tumor cloning assay.
Cancer drug delivery 1986;3(4):273-8.
1986: Morris G L; Zeltzer P M; Schneider S L; Von Hoff D D
Cloning of pediatric malignancies for drug sensitivity testing in the human tumor cloning assay.
The American journal of pediatric hematology/oncology 1986;8(1):52-7.
1986: Hutton J J; Von Hoff D D
Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay.
Cancer drug delivery 1986;3(2):115-22.
1986: Hersh M R; Kuhn J G; Phillips J L; Clark G; Ludden T M; Von Hoff D D
Pharmacokinetic study of fludarabine phosphate (NSC 312887).
Cancer chemotherapy and pharmacology 1986;17(3):277-80.
1985: Lathan B; Clark G M; Von Hoff D D
In vitro comparison of vinzolidine and vinblastine: a model for methods of evaluation of analogues in a human tumor cloning system.
Cancer research 1985;45(12 Pt 1):6286-9.
1985: Green M D; Speyer J; Wernz J; Kisner D; Koeller J; Blum R; Von Hoff D; Muggia F
Doxorubicin and interferon: rationale and clinical experience.
Cancer treatment reviews 1985;12 Suppl B():61-7.
1985: Hanauske A R; Hanauske U; Von Hoff D D
The human tumor cloning assay in cancer research and therapy: a review with clinical correlations.
Current problems in cancer 1985;9(12):1-66.
1985: Hilgers R D; Von Hoff D D; Stephens R L; Boutselis J G; Rivkin S E
Mitoxantrone in adenocarcinoma of the endometrium: a Southwest Oncology Group Study.
Cancer treatment reports 1985;69(11):1329-30.
1985: Lathan B; Edwards D P; Dressler L G; Von Hoff D D; McGuire W L
Immunological detection of Chinese hamster ovary cells expressing a multidrug resistance phenotype.
Cancer research 1985;45(10):5064-9.
1985: Von Hoff D D
Implications of tumor cell heterogeneity for in vitro drug sensitivity testing.
Seminars in oncology 1985;12(3):327-31.
1985: Harris G J; Zeagler J; Von Hoff D D
A method for performing scanning electron microscopy of colonies growing in a human tumor cloning system.
International journal of cell cloning 1985;3(5):286-93.
1985: Von Hoff D D; Forseth B; Warfel L E
Use of a radiometric system to screen for antineoplastic agents: correlation with a human tumor cloning system.
Cancer research 1985;45(9):4032-8.
1985: Weiss G; Von Hoff D D
Human tumor cloning assay: clinical applications for ovarian, gastric, pancreatic, and colorectal cancers.
Seminars in oncology 1985;12(3 Suppl 4):69-74.
1985: Melink T J; Von Hoff D D; Kuhn J G; Hersh M R; Sternson L A; Patton T F; Siegler R; Boldt D H; Clark G M
Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Cancer research 1985;45(6):2859-65.
1985: Douglass H O; MacIntyre J M; Kaufman J; Von Hoff D; Engstrom P F; Klaassen D
Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
Cancer treatment reports 1985;69(5):543-5.
1985: Bull F E; Von Hoff D D; Balcerzak S P; Stephens R L; Panettiere F J
Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
Cancer treatment reports 1985;69(2):231-3.
1985: Weiss G R; Hersh M; Kuhn J G; Ludden T M; von Hoff D D; Kisner D L; Pirtle T E
A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.
Cancer chemotherapy and pharmacology 1985;15(2):144-8.
1985: Taylor S A; Tranum B T; Von Hoff D D; Costanzi J J
Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
Investigational new drugs 1985;3(1):67-9.
1985: Hanauske A R; Von Hoff D D
Clinical correlations with the human tumor cloning assay.
Cancer investigation 1985;3(6):541-51.
1985: Cowan J D; Osborne C K; Neidhart J A; Von Hoff D D; Constanzi J J; Vaughn C B
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Investigational new drugs 1985;3(2):149-52.
1985: Osborne C K; Von Hoff D D; Mullins K
Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay.
Breast cancer research and treatment 1985;6(3):229-35.
1985: Hill K E; Von Hoff D D; Burk R F
Effect of inhibition of gamma-glutamyltranspeptidase by AT-125 (acivicin) on glutathione and cysteine levels in rat brain and plasma.
Investigational new drugs 1985;3(1):31-4.
1984: Von Hoff D D
Use of daunorubicin in patients with solid tumors.
Seminars in oncology 1984;11(4 Suppl 3):23-7.
1984: Mattox D E; Von Hoff D D; McGuire W L
Androgen receptors and antiandrogen therapy for laryngeal carcinoma.
Archives of otolaryngology (Chicago, Ill. : 1960) 1984;110(11):721-4.
1984: Hilgers R D; Rivkin S E; Von Hoff D D; Alberts D S
Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study.
American journal of clinical oncology 1984;7(5):499-501.
1984: Boldt D H; Von Hoff D D; Kuhn J G; Hersh M
Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.
Cancer research 1984;44(10):4661-6.
1984: Coltman C A; Coltman T M; Balcerzak S P; Morrison F S; Von Hoff D D
Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study.
Seminars in oncology 1984;11(3 Suppl 1):50-3.
1984: Hutton J J; Von Hoff D D; Kuhn J; Phillips J; Hersh M; Clark G
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
Cancer research 1984;44(9):4183-6.
1984: Taylor S A; Von Hoff D D; Baker L H; Balcerzak S P
Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
Cancer treatment reports 1984;68(6):919-20.
1984: Sledge G W; Clark G M; Griffin C; Mattox D E; Von Hoff D D
Phase II trial of vindesine in patients with squamous cell cancer of the head and neck.
American journal of clinical oncology 1984;7(3):209-11.
1984: Myers J W; Von Hoff D D; Clark G M; Coltman C A
Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Cancer treatment reports 1984;68(6):927-8.
1984: Lathan B; Von Hoff D D; Elslager E
Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone.
Cancer treatment reports 1984;68(5):733-8.
1984: Myers J W; Von Hoff D D; Kuhn J G; Nusynowitz M; Benedetto A R; Pocelinko R
Radioangiocardiogram monitoring in patients receiving bisantrene.
American journal of clinical oncology 1984;7(2):129-30.
1984: Mattox D E; Von Hoff D D; Clark G M; Aufdemorte T B
Factors that influence growth of head and neck squamous carcinoma in the soft agar cloning assay.
Cancer 1984;53(8):1736-40.
1984: Von Hoff D D; Amato D A; Kaufman J H; Falkson G; Cunningham T J
Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
American journal of clinical oncology 1984;7(2):135-9.
1984: Sledge G W; Clark G M; Von Hoff D D
Phase II trial of vindesine in adenocarcinoma of the lung.
Cancer treatment reports 1984;68(3):557-8.
1984: Bogden A E; Von Hoff D D
Comparison of the human tumor cloning and subrenal capsule assays.
Cancer research 1984;44(3):1087-90.
1984: Osborne C K; Von Hoff D D; Cowan J D; Sandbach J
Bisantrene, an active drug in patients with advanced breast cancer.
Cancer treatment reports 1984;68(2):357-60.
1984: Cowan J D; Von Hoff D D; Neuenfeldt B; Mills G M; Clark G M
Predictive value of trypan blue exclusion viability measurements for colony formation in a human tumor cloning assay.
Cancer drug delivery 1984;1(2):95-100.
1984: Lathan B; Von Hoff D D
Cytotoxic activity of echinomycin in a human tumor cloning system.
Cancer drug delivery 1984;1(3):191-8.
1984: Kisner D L; Mehta P; Paget G E; Von Hoff D D
Activity of Carbetimer in a human tumor cloning system.
Investigational new drugs 1984;2(1):55-8.
1984: Zeltzer P M; Schneider S L; Von Hoff D D
Morphologic, cytochemical and neurochemical characterization of the human medulloblastoma cell line TE671.
Journal of neuro-oncology 1984;2(1):35-45.
1983: Coltman C A; McDaniel T M; Balcerzak S P; Morrison F S; Von Hoff D D
Mitoxantrone hydrochloride in lymphoma.
Cancer treatment reviews 1983;10 Suppl B():73-6.
1983: Osborne C K; Drelichman A; Von Hoff D D; Crawford E D
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Cancer treatment reports 1983;67(12):1133-5.
1983: Mattox D E; Von Hoff D D; Harris L L
Human tumor cloning assay in advanced head and neck cancer. Prospective correlative trial.
Archives of otolaryngology (Chicago, Ill. : 1960) 1983;109(11):724-6.
1983: Loesch D M; Von Hoff D D; Kuhn J; Coltman C A; Tio F; Chaudhuri T K; Bender J F; Grillo-Lopez A J
Phase I investigation of ametantrone.
Cancer treatment reports 1983;67(11):987-91.
1983: Sarosdy M F; Von Hoff D D
Prediction of response to cancer chemotherapy.
Drugs 1983;26(5):454-9.
1983: Kitten C M; Von Hoff D D; Bennett E V; Trinkle J K; Grover F L
The human tumor clonogenic assay in the treatment of patients with lung cancer.
The Annals of thoracic surgery 1983;36(4):408-10.
1983: Casper J T; Trent J M; Harb J; Piaskowski V; Helmsworth M; Finlan J; Von Hoff D D
Distinguishing characteristics of a new neuroblastoma cell line.
Cancer genetics and cytogenetics 1983;10(2):177-86.
1983: Mattox D E; Sternson L A; Von Hoff D D; Kuhn J G; Repta A J
Tumor concentration of platinum in patients with head and neck cancer.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1983;91(3):271-5.
1983: Metelmann H R; Von Hoff D D
In vitro activation of dacarbazine (DTIC) for a human tumor cloning system.
International journal of cell cloning 1983;1(1):24-32.
1983: Von Hoff D D; Clark G M; Stogdill B J; Sarosdy M F; O'Brien M T; Casper J T; Mattox D E; Page C P; Cruz A B; Sandbach J F
Prospective clinical trial of a human tumor cloning system.
Cancer research 1983;43(4):1926-31.
1983: Von Hoff D D; Chen T; Clark G M; Callahan S K; Livingston R
Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: a Southwest Oncology Group Study.
Cancer treatment reports 1983;67(4):403-4.
1983: Cowan J D; Von Hoff D D; Dinesman A; Clark G
Use of a human tumor cloning system to screen retinoids for antineoplastic activity.
Cancer 1983;51(1):92-6.
1983: Von Hoff D D
"Send this patient's tumor for culture and sensitivity".
The New England journal of medicine 1983;308(3):154-5.
1983: Kuhn J G; Ludden T M; Myers J W; Von Hoff D D
Characterization of the pharmacokinetics of bisantrene (NSC-337766).
Investigational new drugs 1983;1(3):253-7.
1983: Knight W A; Von Hoff D D; Neidhart J A; Tranum B L; Fabian C; Jones S E
Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group.
Investigational new drugs 1983;1(2):181-4.
1983: Cowan J D; Von Hoff D D; Clark G M
Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system.
Investigational new drugs 1983;1(2):139-44.
1983: Myers J W; Von Hoff D D; Kuhn J G; Osborne C K; Sandbach J F; Pocelinko R
Anaphylactoid reactions associated with bisantrene infusions.
Investigational new drugs 1983;1(1):85-8.
1983: Coltman C A; McDaniel T M; Balcerzak S P; Morrison F S; Von Hoff D D
Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study.
Investigational new drugs 1983;1(1):65-70.
1983: Metelmann H R; Von Hoff D D
Application of a microsomal drug activation system in a human tumor cloning assay.
Investigational new drugs 1983;1(1):27-32.
1982: Forastiere A A; Crain S M; Callahan K; Van Echo D; Mattox D; Thant M; Von Hoff D D; Wiernik P H
Phase II trial of aziridinylbenzoquinone (AZQ) in head and neck cancer.
Cancer treatment reports 1982;66(12):2097-8.
1982: Myers J W; Von Hoff D D; Coltman C A; Kuhn J G; Van Echo D; Rivkin S; Pocelinko R
Phase II evaluation of bisantrene in patients with renal cell carcinoma.
Cancer treatment reports 1982;66(10):1869-71.
1982: Sandbach J; Von Hoff D D; Clark G; Cruz A B; Obrien M
Direct cloning of human breast cancer in soft agar culture.
Cancer 1982;50(7):1315-21.
1982: Sarosdy M F; Lamm D L; Radwin H M; Von Hoff D D
Clonogenic assay and in vitro chemosensitivity testing of human urologic malignancies.
Cancer 1982;50(7):1332-8.
1982: Cowan J D; Von Hoff D D; McDonald B; Talley R W; McCracken J D; Chen T
Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
Cancer treatment reports 1982;66(9):1779-80.
1982: Bhuyan B K; Newell K A; Crampton S L; Von Hoff D D
CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival.
Cancer research 1982;42(9):3532-7.
1982: Harris G J; Zeagler J; Hodach A; Casper J; Harb J; Von Hoff D D
Ultrastructural analysis of colonies growing in a human tumor cloning system.
Cancer 1982;50(4):722-6.
1982: Von Hoff D D; Forseth B; Metelmann H R; Harris G; Rowan S; Coltman C A
Direct cloning of human malignant melanoma.
Cancer 1982;50(4):696-701.
1982: McGovren J P; Stewart J C; Elfring G L; Smith R B; Soares N; Wood J H; Poplack D G; Von Hoff D D
Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys.
Cancer treatment reports 1982;66(6):1333-41.
1982: Von Hoff D D; Rozencweig M; Piccart M
The cardiotoxicity of anticancer agents.
Seminars in oncology 1982;9(1):23-33.
1982: Kitten C M; Von Hoff D D; Bennett E V; Grover F L
Growth of lung cancer in a human tumor clonogenic system.
The Journal of thoracic and cardiovascular surgery 1982;83(3):363-71.
1982: Von Hoff D D; Swenerton K D; Hetanen L; Gafney E; Rivkin S; Schuchart S; Coltman C A
Long-distance transportation of specimens for human tumor cloning.
Stem cells 1982;2(2):122-8.
1982: Elson D L; Osborne C K; Livingston R B; Von Hoff D D
Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition.
Stem cells 1982;2(1):34-44.
1982: Von Hoff D D; Gutterman J; Portnoy B; Coltman C A
Activity of human leukocyte interferon in a human tumor cloning system.
Cancer chemotherapy and pharmacology 1982;8(1):99-103.
1981: Salmon S E; Von Hoff D D
In vitro evaluation of anticancer drugs with the human tumor stem cell assay.
Seminars in oncology 1981;8(4):377-85.
1981: Mullen B M; Mattox D E; Von Hoff D D; Hearne E M
The effect of preoperative adriamycin and dihydroxyanthracenedione on wound healing.
The Laryngoscope 1981;91(9 Pt 1):1436-43.
1981: Von Hoff D D; Myers J W; Kuhn J; Sandbach J F; Pocelinko R; Clark G; Coltman C A
Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).
Cancer research 1981;41(8):3118-21.
1981: Von Hoff D D; Weisenthal L M; Ihde D C; Mathews M J; Layard M; Makuch R
Growth of lung cancer colonies from bronchoscopy washings.
Cancer 1981;48(2):400-3.
1981: Von Hoff D D; Casper J; Bradley E; Sandbach J; Jones D; Makuch R
Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy.
The American journal of medicine 1981;70(5):1027-41.
1981: Von Hoff D D; Coltman C A; Forseth B
Activity of mitoxantrone in a human tumor cloning system.
Cancer research 1981;41(5):1853-5.
1981: Von Hoff D D; Howser D; Lewis B J; Holcenberg J; Weiss R B; Young R C
Phase I study of ICRF-187 using a daily for 3 days schedule.
Cancer treatment reports 1981;65(3-4):249-52.
1981: Pollard E B; Tio F; Myers J W; Clark G; Coltman C A; Von Hoff D D
Utilization of a human tumor cloning system to monitor for marrow involvement with small cell carcinoma of the lung.
Cancer research 1981;41(3):1015-20.
1981: Chiuten D F; Rozencweig M; Von Hoff D D; Muggia F M
Clinical trials with the hexitol derivatives in the U.S.
Cancer 1981;47(3):442-51.
1981: Vistica D T; Von Hoff D D; Torain B
Uptake of melphalan by human ovarian carcinoma cells and its relationship to the amino acid content of ascitic fluid.
Cancer treatment reports 1981;65(1-2):157-61.
1981: Fuks J Z; Van Echo D A; Aisner J; Von Hoff D; Wiernik P H
Phase II trial of AMSA in patients with refractory small cell carcinoma of the lung.
Cancer treatment reports 1981;65(1-2):133-4.
1981: Von Hoff D D; Sandbach J; Osborne C K; Metelmann C; Clark G M; O'Brien M
Potential and problems with growth of breast cancer in a human tumor cloning system.
Breast cancer research and treatment 1981;1(2):141-8.
1981: Von Hoff D D; Cowan J; Harris G; Reisdorf G
Human tumor cloning: feasibility and clinical correlations.
Cancer chemotherapy and pharmacology 1981;6(3):265-71.
1981: Von Hoff D D; Coltman C A; Forseth B
Activity of 9-10 anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride (CL216,942) in a human tumor cloning system. Leads for phase II trials in man.
Cancer chemotherapy and pharmacology 1981;6(2):141-4.
1981: Von Hoff D D; Kuhn J; Clark G
Does color of an antitumor agent predict for clinical antitumor activity?
Cancer chemotherapy and pharmacology 1981;6(1):93-4.
1981: Von Hoff D D; Layard M
Risk factors for development of daunorubicin cardiotoxicity.
Cancer treatment reports 1981;65 Suppl 4():19-23.
1981: Rozencweig M; Abele R; von Hoff D D; Muggia F M
Cisplatin: impact of a new anticancer agent on current therapeutic strategies.
Anticancer research 1981;1(4):199-204.
1981: Rozencweig M; Von Hoff D D; Staquet M J; Schein P S; Penta J S; Goldin A; Muggia F M; Freireich E J; DeVita V T
Animal toxicology for early clinical trials with anticancer agents.
Cancer clinical trials 1981;4(1):21-8.
1981: Glaubiger D L; von Hoff D D; Holcenberg J S; Kamen B; Pratt C; Ungerleider R S
The relative tolerance of children and adults to anticancer drugs.
Frontiers of radiation therapy and oncology 1981;16():42-9.
1981: Von Hoff D D; Alberts D S; Mattox D E; Coulthard S; Dana B; Manning M; Myers J W; Griffin C B
Combination chemotherapy with cisplatin, bleomycin, and methotrexate in patients with advanced head and neck cancer.
Cancer clinical trials 1981;4(2):215-8.
1980: Mattox D E; Von Hoff D D
Culture of human head and neck cancer stem cells using soft agar.
Archives of otolaryngology (Chicago, Ill. : 1960) 1980;106(11):672-4.
1980: Bradley E C; Reichert C M; Brennan M F; Von Hoff D D
Direct cloning of human parathyroid hyperplasia cells in soft-agar culture.
Cancer research 1980;40(10):3694-6.
1980: Mattox D E; Von Hoff D D
In vitro stem cell assay in head and neck squamous carcinoma.
American journal of surgery 1980;140(4):527-30.
1980: Von Hoff D D; Casper J; Bradley E; Trent J M; Hodach A; Reichert C; Makuch R; Altman A
Direct cloning of human neuroblastoma cells in soft agar culture.
Cancer research 1980;40(10):3591-7.
1980: Von Hoff D D; Pollard E; Kuhn J; Murray E; Coltman C A
Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
Cancer research 1980;40(5):1516-8.
1980: von Hoff D D; Soares N; Gormley P; Poplack D G
Pharmacokinetics of ICRF-187 in the cerebrospinal fluid of subhuman primates.
Cancer treatment reports 1980;64(4-5):734-6.
1980: Von Hoff D D; Elson D; Polk G; Coltman C
Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).
Cancer treatment reports 1980;64(2-3):356-8.
1980: Rozencweig M; Abele R; Piccart M; Von Hoff D D; Muggia F M
N-(Phosphonacetyl)-L-aspartate (PALA): current status.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1980;74():72-7.
1980: Von Hoff D D; Harris G J; Johnson G; Glaubiger D
Initial experience with the human tumor stem cell assay system: potential and problems.
Progress in clinical and biological research 1980;48():113-24.
1980: Casper J T; Trent J M; Von Hoff D D
Cloning of human neuroblastoma cells in soft agar.
Progress in clinical and biological research 1980;48():101-11.
1980: Kressner B E; Morton R R; Martens A E; Salmon S E; Von Hoff D D; Soehnlen B
Use of an image analysis system to count colonies in stem cell assays of human tumors.
Progress in clinical and biological research 1980;48():179-93.
1980: Rozencweig M; Von Hoff D D; Allegra J C; Muggia F M
Surgical adjuvant trials in the United States.
European journal of cancer 1980;Suppl 1():173-7.
1980: Von Hoff D D; Weisenthal L
In vitro methods to predict for patient response to chemotherapy.
Advances in pharmacology and chemotherapy 1980;17():133-56.
1980: Rozencweig M; Von Hoff D D; Legha S S; Cysyk R L; Muggia F M
m-AMSA: a new anticancer agent.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1980;74():250-7.
1980: Falkson G; Von Hoff D; Klaassen D; Du Plessis H; Van Der Merwe C F; Van Der Merwe A M; Carbone P P
A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study.
Cancer chemotherapy and pharmacology 1980;4(1):33-6.
1979: Staquet M J; Rozencweig M; Von Hoff D D; Muggia F M
The delta and epsilon errors in the assessment of cancer clinical trials.
Cancer treatment reports 1979;63(11-12):1917-21.
1979: Von Hoff D D; Layard M W; Basa P; Davis H L; Von Hoff A L; Rozencweig M; Muggia F M
Risk factors for doxorubicin-induced congestive heart failure.
Annals of internal medicine 1979;91(5):710-7.
1979: Young R C; Von Hoff D D; Gormley P; Makuch R; Cassidy J; Howser D; Bull J M
cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer.
Cancer treatment reports 1979;63(9-10):1539-44.
1979: Von Hoff D D; Schilsky R; Reichert C M; Reddick R L; Rozencweig M; Young R C; Muggia F M
Toxic effects of cis-dichlorodiammineplatinum(II) in man.
Cancer treatment reports 1979;63(9-10):1527-31.
1979: Von Hoff D D; Rozencweig M; Muggia F M
The evaluation of cytotoxic drugs.
Cancer treatment reviews 1979;6 Suppl():1-8.
1979: Catane R; Von Hoff D D; Glaubiger D L; Muggia F M
Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity.
Cancer treatment reports 1979;63(6):1033-8.
1979: Rozencweig M; De Sloover C; Von Hoff D D; Tagnon H J; Muggia F M
Anthracycline derivatives in new drug development programs.
Cancer treatment reports 1979;63(5):807-8.
1979: Rozencweig M; Von Hoff D D; Cysyk R L; Muggia F M
m-AMSA and PALA: two new agents in cancer chemotherapy.
Cancer chemotherapy and pharmacology 1979;3(3):135-41.
1979: Von Hoff D D; Rozencweig M
cis-Diamminedichloroplatinum(II): a metal complex with significant anticancer activity.
Advances in pharmacology and chemotherapy 1979;16():273-98.
1978: Rozencweig M; Zelen M; Von Hoff D D; Muggia F M
Sounding board. Waiting for a bus: Does it explain age-dependent differences in response to chemotherapy of early breast cancer?
The New England journal of medicine 1978;299(24):1363-4.
1978: Von Hoff D D; Dunnick N R
The case of the triangular foreign body.
JAMA : the journal of the American Medical Association 1978;240(19):2044-5.
1978: Von Hoff D D; Howser K; Gormley P; Bender R A; Glaubiger D; Levine A S; Young R C
Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
Cancer treatment reports 1978;62(10):1421-6.
1978: Von Hoff D D; Rozencweig M; Louie A C; Bender R A; Muggia F M
"Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.
Cancer treatment reports 1978;62(2):233-5.
1978: Davis H L; von Hoff D D
Evaluation and role of single chemotherapeutic agents in adult non-Hodgkin's lymphoma.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1978;65():129-44.
1978: Von Hoff D D; Rozencweig M; Slavik M
Daunomycin: an anthracycline antibiotic effective in acute leukemia.
Advances in pharmacology and chemotherapy 1978;15():1-50.
1978: Rozencweig M; von Hoff D D; Louie A C; Muggia F M
Current trends and prospects in surgical adjuvant trials.
Archiv für Geschwulstforschung 1978;48(7):673-9.
1978: Louie A C; Rozencweig M; von Hoff D D; Muggia F M
Effective adjuvant treatments. A brief review of U.S. clinical trials.
Archiv für Geschwulstforschung 1978;48(7):653-8.
1978: Davis H L; von Hoff D D; Henney J E; Rozencweig M
The role of antitumor antibiotics in current oncologic practice.
Cancer chemotherapy and pharmacology 1978;1(2):83-90.
1978: Davis H L; von Hoff D D; Henney J E; Rozencweig M
Role of antitumor antibiotics in current oncologic practice.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1978;63():21-9.
1977: Von Hoff D D; Rozencweig M; Muggia F M
Cytembena: an anticancer drug with an unique structure.
Biomedicine / [publiée pour l'A.A.I.C.I.G.] 1977;26(6):388-92.
1977: Rozencweig M; Von Hoff D D; Muggia F M
Investigational chemotherapeutic agents in head and neck cancer.
Seminars in oncology 1977;4(4):425-9.
1977: Bellet R E; Rozencweig M; Von Hoff D D; Penta J S; Wasserman T H; Muggia F M
ICRF-159: current status and clinical prospects.
European journal of cancer 1977;13(11):1293-8.
1977: Von Hoff D D; Layard M; Rozencweig M; Muggia F M
Time relationship between last dose of daunorubicin and congestive heart failure.
Cancer treatment reports 1977;61(7):1411-3.
1977: Von Hoff D D; Rozencweig M; Soper W T; Helman L J; Penta J S; Davis H L; Muggia F M
Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents.
Cancer treatment reports 1977;61(5):759-68.
1977: Penta J S; Von Hoff D D; Muggia F M
Hepatotoxicity of combination chemotherapy for acute myelocytic leukemia.
Annals of internal medicine 1977;87(2):247-8.
1977: Rozencweig M; Von Hoff D D; Henney J E; Muggia F M
VM 26 and VP 16-213: a comparative analysis.
Cancer 1977;40(1):334-42.
1977: Von Hoff D D; Penta J S; Helman L J; Slavik M
Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.
Cancer treatment reports 1977;61(4):745-8.
1977: Rozencweig M; von Hoff D D; Slavik M; Muggia F M
Cis-diamminedichloroplatinum (II). A new anticancer drug.
Annals of internal medicine 1977;86(6):803-12.
1977: Von Hoff D D; Rozencweig M; Slavik M; Muggia F M
Estramustine phosphate: a specific chemotherapeutic agent?.
The Journal of urology 1977;117(4):464-6.
1977: Louie A; Von Hoff D D; Rozencweig M; Muggia F
Adjuvant chemotherapy: correct advice.
JAMA : the journal of the American Medical Association 1977;237(16):1691.
1977: Von Hoff D D; Rozencweig M; Layard M; Slavik M; Muggia F M
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.
The American journal of medicine 1977;62(2):200-8.
1977: Mikulski S W; Von Hoff D D; Rozencweig M; Muggia F M
Tuftsin - unimportant or forgotten.
The New England journal of medicine 1977;296(8):454.
1977: von Hoff D D; Slavik M
5-azacytidine--a new anticancer drug with significant activity in acute myeloblastic leukemia.
Advances in pharmacology and chemotherapy 1977;14():285-326.
1976: Von Hoff D D; Rozencweig M; Slavik M; Muggia F M
Activity of daunomycin in solid tumors.
JAMA : the journal of the American Medical Association 1976;236(15):1693.
1976: Von Hoff D D; Slavik M; Muggia F M
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia.
Annals of internal medicine 1976;85(2):237-45.
1976: Von Hoff D D; Slavik M; Muggia F M
Letter: Allergic reactions to cis platinum.
Lancet 1976;1(7950):90.
1976: Legha S S; Von Hoff D D; Rozencweig M; Abraham D; Slavik M; Muggia M
Neocarzinostatin (NSC 157365) a new cancerostatic compound.
Oncology 1976;33(5-6):265-70.
1975: Von Hoff D D; Luckey M; Wallace J; Fitzgerald F
Herpes type 2 meningitis following herpes progenitalis.
The Western journal of medicine 1975;123(6):490-1.
1975: Von Hoff D D; LiVolsi V
Diagnostic reliability of needle biopsy of the parietal pleura. A review of 272 biopsies.
American journal of clinical pathology 1975;64(2):200-3.
1974: Von Hoff D D; Kimball R S
Letter: Eikenella corrodens infection.
Annals of internal medicine 1974;81(2):273-4.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Daniel Von Hoff

Research Profile (preview)

Chemicals & Drugs

Disorders

Activities & Behaviors

Procedures

Anatomy

Concepts & Ideas

Living Beings

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Daniel Von Hoff (preview)

All Publications